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THESIS 
SINGLE-MOLECULE ANALYSIS 
OF ALZHEIMER'S β-PEPTIDE OLIGOMER DISASSEMBLY 
AT PHYSIOLOGICAL CONCENTRATION 
ABSTRACT OF THESIS 
The diffusible soluble oligomeric amyloid β-peptide (Aβ) has been identified as a toxic agent 
in Alzheimer’s disease that can cause synaptic dysfunction and memory loss, indicating its 
role as potential therapeutic targets for AD treatment. Recently an oligomer-specific sandwich 
biotin-avidin interaction based assay identified the Aβ oligomer dissociation potency of a 
series of dihydroxybenzoic acid (DHBA) isomers. Because the sandwich assay is an ensemble 
method providing limited size information, fluorescence correlation spectroscopy (FCS) was 
employed to provide single molecule resolution of the disassembly mechanism. 
Using FCS coupled with atomic force microscopy, we investigated the size distribution of 
fluorescein labeled synthetic Aβ oligomers at physiological concentrations, and monitored in 
real time the change of size and mole fraction of oligomers in the presence of dissociating 
agents or conditions. The higher-order dissociation process caused by DHBA isomers 
produced no transient oligomeric intermediates, a desirable feature for an anti-oligomer 
therapeutic. Urea and guanidine hydrochloride, in contrast, produced a linear dissociation 
with a progressive decrease of size and mole fraction of oligomers. FCS allows the facile 
distinction of small molecule Aβ oligomer dissociators that do not produce stable potentially 
toxic oligomeric Aβ intermediates.  
KEYWORDS: Alzheimer’s disease, soluble amyloid-β oligomers, Aβ, oligomer dissociators, 
fluorescence correlation spectroscopy, atomic force microscopy, dissociation mechanism 
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Chapter One: Introduction 
1.1 Alzheimer’s disease and “amyloid cascade hypothesis”  
1.1.1 Overview of Alzheimer’s disease 
 
Alzheimer‟s disease (AD) is the most common form of dementia in many people, over the age 
of 65 [1]. As the most prevalent neurodegenerative disease [2], AD is clinically characterized 
by a progressive decline of cognitive function in multiple brain functions such as memory, 
thought, and behavior [3] in addition to interfering with the individuals‟ activities of daily life 
living. AD therefore imposes an enormous economic burden on society [4] and has become a 
serious social problem. According to recent estimates by Alzheimer‟s Disease International, in 
2010 as many as 36 million people worldwide have AD at a resulting global cost of $604 
billion [5].  
  
There are two pathological hallmarks which are essential for a diagnosis of AD, 
extracellularly deposited amyloid plaques composed of amyloid-β (Aβ) peptide, 39-43 amino 
acids in the brain parenchyma, and intracellular neurofibrillary tangles of aggregates of 
hyperphosphorylated tau protein [6].  
 
1.1.2 Genesis of the “amyloid cascade hypothesis” 
. 
Amyloid plaques were first described as a disease feature by the Bavarian psychiatrist Alois 
Alzheimer in 1906 [7], after his histological examination of the brain from his patients with 
AD. In 1984 Glenner and Wong isolated and identified a unique 4200 dalton protein from 
cerebrovascular amyloid fibril deposit in AD brain they named amyloid β-protein. They 
proposed that it might be derived from a unique serum precursor, which would lead to a 
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specific diagnosis for AD [8]. The protein comprising the hallmark neurofibrillary tangles 
was identified in the two years later. Hyperphosphorylated microtubule-associated tau protein 
was found in the paired helical filaments (PHF) inside neurons in AD. The role of tau 
pathology in AD became another interesting topic. 
  
Aβ-containing amyloid plaques and neurofibrillary tangles (NFTs) were also found in the 
brains of the middle-aged patients with Down syndrome (DS). Thus, it was hypothesized by 
Glenner with his discovery of Aβ in cerebrovascular amyloid deposits from young patients 
with DS, that the gene encoding the amyloid precursor protein (APP), might be a causative 
gene for AD [9]. He postulated that the causative gene for AD was localized on the Down 
trisomic chromosome 21. This was confirmed subsequently by the work of Beyreuther‟s 
group [10].  
 
The amyloid cascade hypothesis received major support in 1990 by the discovery of 
AD-causing mutation in a Dutch family with hereditary cerebral hemorrhage with 
amyloidosis, an autosomal dominant form of Aβ amyloidosis. A cytosine-to-guanine 
transversion mutation at amino acid 22 of the amyloid protein resulting in the change E22Q 
was detected and considered to initiate the deposition of the amyloid protein in the 
cerebrovasculature, which is similar to Aβ in AD and DS. One year later a cytosine-thymine 
missense mutation which caused a valine to isoleucine change at amino acid 717 in APP was 
found in a family with early-onset AD [11], along with subsequently identified mutations, this 
was taken to indicate that Aβ deposition is the central event in the pathogenesis of AD. These 
findings eventually led to the proposal of the “amyloid cascade hypothesis”. 
 
1.1.3 Classical “amyloid cascade hypothesis” 
 
The amyloid cascade hypothesis (Figure 1.1), proposed by John Hardy in 1992, states that the 
aggregation and deposition of Aβ peptide initiates a process resulting in the human 
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neurodegeneration of AD [12]. Familial early onset forms of AD have been described as 
resulting from mutations in three different genes: the amyloid precursor protein (APP), 
presenilin-1 (PS1) and presenilin-2 (PS2). PS1 and PS2 are both homologous proteins that 
can provide the catalytic active site of γ-secretase. 
  
The majority of type I transmembrane protein APP is processed by α-secretase, releasing the 
APPα ectodomain and a C-terminal fragment CTFα of 83 amino acids. CTFα is further 
cleaved by γ-secretase to liberate a non-toxic 23-26 amino acid p3 peptide as well as the APP 
intracellular domain (AICD). About 10% of APP is processed by the β-site APP cleaving 
enzyme (BACE) or so called β-secretase, releasing a large ectodomain of APPβ. The 
remaining membrane C-terminal fragment, CTFβ, containing 99 amino acids, is subsequently 
cleaved within the lipid bilayer by γ-secretase (presenilins 1 and 2), to produce amyloid 
β-protein (Aβ) and AICD. Aβ peptide spontaneously aggregates into fibrils containing cross 
β-sheet structure and deposits in senile plaques in the brain parenchyma or in blood vessel 
walls. Those fibrils and plaques can induce synaptic dysfunction and neuronal toxicity 
directly or indirectly by inducing cellular changes that result in the formation of the 
intracellular neurofibrillary tangles (NFTs) consisting of paired helical filaments (PHFs) from 
hyperphosphorylated tau protein, eventually resulting in AD and dementia [13].  
 
Figure 1.1. Classical “amyloid cascade hypothesis” 
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1.1.4 Misfolded Aβ assembly pathway: oligomers and fibrils  
 
The secretase-cleaved Aβ peptides with 39-42 amino acid residues are released from the cell 
and can convert from random coil to cross β strand or α-helix in the formation of Aβ fibrils 
[14]. Even though Aβ monomers are relative harmless, and may serve some positive 
biological function, they can also self-assemble via a nucleation-dependent pathway (Figure 
1.2) into soluble Aβ oligomers, larger Aβ aggregation intermediates, protofibrils, and 
eventually the fibrillar aggregates that deposit in the brain [15].  
 
Those soluble oligomers ranging from low molecular weight (~2-8 monomers) to high 
molecular weight (~20-40 monomers) species appear in the early stages of aggregation from 
monomers to insoluble fibrils following classical polymerization kinetics. In addition, off 
pathway oligomers, or called “prefibrillar oligomers” which do not directly continue on to 
form fibrils, have also been identified [16], indicating that there are at least two independent 
Aβ assembly pathways, one leading to off pathway oligomers and the other to fibrils. These 
two different types of oligomers, prefibrillar oligomers and fibrillar oligomers can be 
distinguished by conformational epitope-specific antibodies. The fibrillar specific antibody, 
OC, only recognizes the generic fibrillar lattice structure of fibrillar oligomers protofibrils, or 
mature fibrils. Another antibody, A11, only recognizes a generic epitope of prefibrillar 
oligomers [17]. The definition of “soluble” refers to Aβ in aqueous buffer that is not pelleted 
after high-speed centrifugation (100,000 xg, 1 hour) [18]. Synthetic oligomers have different 
sizes and structure as well as morphology resulting from different sample preparation 
processes. The relationship between synthetic and biological oligomers structure, stability, 
and biological activity is unknown and is the topic of intense debate. Due to the surfactant 
properties of axially amphipathic Aβ peptide, synthetic oligomers likely have a micellar 
structure with a hydrophobic core stabilized by the “hydrophobic effect” [19]. 
 
Fibril formation is frequently nucleated on extracellular matrix or cell surfaces. The structure 
of short synthetic peptide amyloid fibrils is recently described as “steric zippers” with a 
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cross-β spine composed of a pair of parallel hydrogen-bonded β-sheet strands [20]. The 
nucleation and elongation of fibril for both synthetic and AD brain deposited fibrils is 
proportional to the Aβ monomer concentration [21]. The synthetic fibrils are usually prepared 
at relatively high concentrations of peptide. Amyloid fibrils from different proteins or even 
growing from identical sequences can have different structural detail and conformations as 
polymorphisms on the basic cross-β sheet backbone as detected by relative seeding 
efficiencies, indicating high sensitivity to point mutations at certain positions in the Aβ and 
high specificity in general seeding of fibril elongation [22]. Aβ assembly pathway is 
thermodynamically a reversible process, and deposited fibrils could disassemble into soluble 
oligomers, although this is kinetically slow. A recent study suggests that large insoluble Aβ 
deposits might be a potential reservoir for soluble oligomers [23]. Extrapolation to biological 
systems, in particular to the human condition is poorly studied. 
 
 
 
 
 
Figure 1.2. Schematic diagram of Aβ aggregation process 
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1.1.5 Misfolded proteins in other neurodegenerative diseases   
 
The presence of intra- or extracellular amyloid deposits of misfolded, aggregated  proteins in 
the brain have been identified in other neurodegenerative disease, including Parkinson‟s 
disease (PD), Huntington‟s disease (HD), transmissible spongiform encephalopathies (TSE), 
and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) [24]. Amyloids have 
traditionally been defined by their solubility, morphology and ability to bind dyes, like Congo 
red with birefringence and thioflavin T with a specific fluorescence change. 
 
The protein, α-synuclein, was found as the major component of the cytopathological 
hallmarks in PD, Lewy bodies and Lewy neurites, observed in the cytoplasm. Natively 
unfolded (intrinsically disordered) in solution, α-synuclein is a soluble cytoplasmic protein 
that is highly expressed in neurons, containing an α-helical region, which helps bind to the 
phospholipid membranes of synaptic vesicles [25]. In HD, diffuse, severe atrophy of the 
neostriatum is the diagnosis hallmark in HD, of which the polyglutamine-rich protein 
huntingtin aggregates in neuronal intranuclear and cytoplasmic inclusions [26]. In TSE, or 
prion disease, a fundamental event is responsible for the neurotoxicity, which describes the 
conversion from natively folded glycoprotein PrPC to pathogenic conformation PrPSc which 
is protease-resistant and assembles in amyloid and other deposits [27]. The misfolding of 
copper–zinc superoxide dismutase (SOD 1) and conversion from soluble SOD1 to amyloid 
fibrils in the spinal cord is thought to be the main cause of a subset of familial and ALS [28].  
 
Interestingly, amyloid fibrils share similar morphology and structure even though the specific 
composing protein for each disease has different sequences. The conformation-dependent 
anti-oligomer and anti-fibril antibodies recognize the oligomers and the fibrils regardless of 
sequence, indicating the possible existence of a common pathogenic mechanism [29]. 
 
However the mechanism by which aggregation of misfolded proteins leads to synaptic 
dysfunction in neurodegenerative disorders remains to be clarified. Thus, the study of the 
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experimentally accessible Aβ assembly-disassembly mechanism in AD could provide a 
general model system which could be applicable to other diseases.  
 
1.1.6 Modified amyloid hypothesis: relation between amyloid plaques and neurofibrillary 
tangles   
 
There are 2 different types of protein deposits, amyloid plaques (APs) and neurofibrillary 
tangles (NFTs) in AD pathology. APs are extracellular deposits of insoluble Aβ fibrils in the 
parenchyma and around the cerebral blood vessel walls, with 39- 42 amino acids and the main 
component are Aβ1-40 and Aβ1-42. In contrast, usually deposited intracellularly in the 
cytoplasm of degenerating neurons, NFTs are composed of paired helical filaments (PHF) 
formed from hyperphosphorylated tau. However, it was controversial which one occurs early 
in the disease process and whether they contribute equally to cognitive decline since the early 
description about AD has been based on the studies of AD brain at the end stage. 
 
This was clarified by clinicopathologic studies of AP and NFT with the AD brain samples at 
different stages [30]. The presence of APs and NFTs in autopsy specimens from multiple 
cortical regions was compared, among elderly non-AD subjects (cognitively normal) and 
subjects with different severity of AD evaluated by their last cognitive test, a Mini-Mental 
State Examination, before death. Before significant cognitive deficits were observed, the 
significant differences were in the amounts of APs, suggesting that amyloid plaques are 
related to the earliest cognitive signs of AD. In later stages of pathology the severity of 
dementia was much more closely related to NFT burden than to Aβ deposition, even though 
the density of both pathologies increased with the severity of AD, suggesting that NFTs as 
major markers of severe cognitive impairment and dementia [31].  
 
As a result, the “amyloid cascade hypothesis” was modified considering the role of later stage 
tau pathology where NFTs are present. This is supported by the finding that mutations in the 
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tau gene cause autosomal dominantly inherited dementia linked to chromosome 17 
(FTPD-17), indicating that tau pathology is sufficient to cause neuronal loss [32]. The tau 
deposition occurs in different brain regions and affects different brain functional modalities 
than in AD. Thus, in AD, tau pathology is believed by many to act downstream of Aβ 
pathology [33] . 
 
In summary, cognitive impairment in Alzheimer disease appears to be driven by amyloid 
plaques and neurofibrillary tangles at different stages of the disease, as described by the 
modified “amyloid cascade hypothesis”. The aggregation and deposition of Aβ, occurs at a 
very early stage initiating synaptic dysfunction and triggering tau pathology. Tau pathology 
develops downstream of Aβ pathology, correlates tightly with neuronal loss, and eventually 
AD-type dementia. 
 
1.2 Toxic soluble Aβ oligomers 
1.2.1 Soluble Aβ oligomers: major toxins in AD 
 
Since the “amyloid cascade hypothesis” was first proposed by John Hardy and David Allsop 
[12] nearly one decade ago, it has long been hypothesized that extracellular plaques of Aβ 
fibrils induce neurodegeneration in AD, as those insoluble fibrillar assemblies are found 
neurotoxic in vitro [34]. Yet recent studies show that the level of senile plaques is relatively 
weakly correlated with the severity of dementia or other cognitive alterations, either in human 
or in the mouse model of AD [35,36]. Non-demented individuals have been reported that have 
same amount of insoluble amyloid deposits as cognitively impaired subjects. This disparity 
led to further modification of the cascade hypothesis by suggesting that the primary toxic 
species in AD are soluble prefibrillar or fibrillar oligomeric aggregates formed in the early 
stage of aggregation, rather than the mature fibrils [37,38].  
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The classic “amyloid cascade hypothesis” has been modified over the years when it became 
clearer that there was a more robust correlation between the level of soluble oligomeric, rather 
than fibrillar Aβ and the extent of cognitive impairment, dementia, and disease severity [39]. 
Lambert et al. [40] reported that soluble synthetic Aβ1-42 oligomers, assembled in the 
absence of fibril formation, and named Abeta-derived diffusible ligands (ADDLs), were 
responsible for death of neurons in rat embryonic organotypic central nervous system cultures. 
Electrophysiological studies with protofibrils (PF), metastable intermediates in amyloid fibril 
formation, showed the ability of those earlier Aβ assemblies, especially high molecular 
weight species, to induce toxicity in primary neuronal cultures without any evidence of 
significant conversion to fibrils [41]. Furthermore, intracerebral microinjection of cell culture 
medium containing biological Aβ oligomers blocked long-term potentiation (LTP) in the rat 
hippocampus in vivo, a mechanism thought to be relate  synaptic plasticity to both learning 
and memory [42]. A 56-kDa soluble oligomeric amyloid-β assembly, Aβ56*, purified from 
the brains of cognitively impaired Tg2576 mice, induced a similar synaptotoxic effect and 
disrupted memory when infused into the brain of normal rats [43]. These studies strongly 
support the hypothesis that non-fibrillar oligomeric forms of Aβ are potential toxic agents in 
AD.  
 
1.2.2 Other toxic forms of Aβ present in AD brain 
 
Beside the Aβ1-40 and Aβ1-42, various N- and C-terminal chemical modifications have been 
found through in vitro and in vivo analyses of amyloid deposits in AD [44,45,46], which also 
strongly influence and thus may play important roles in amyloid-β peptide aggregation and 
deposition.  
 
A recent study suggested Aβ1-43, as a novel toxic peptide in AD. This longer and more 
hydrophobic peptide has a higher propensity to aggregate and is more neurotoxic than Aβ42 
[47]. Moreover, several N-terminal truncation and modifications such as pyroglutamate 
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formation of Aβ have also been reported. Aβ4–42 was detected as a relatively abundant 
species in the Aβ1-42 fraction the predominant form of extracted Aβ present in the brain of 
AD and vascular dementia patients [48]. AβpE3, starting with pyroglutamate by cyclization at 
residue Glu-3 was reported to present in equivalent or larger amounts than full-length Aβ in 
senile plaques, which was confirmed by the analysis of water-soluble Aβ, indicating 
AβpE3-42 is the predominant Aβ species in AD and Down syndrome [49]. Portelius et al. 
showed by employment of immunoprecipitation and mass spectrometry, that Aβ1–40, Aβ1–42, 
AβpE3–42, and Aβ4–42 are the dominant plaque components in the brains of sporadic AD 
and familial AD [50]. Many studies demonstrated that N-terminal deletions and modifications 
can enhance Aβ aggregation, generating more toxic species than wild type Aβ. Moreover, 
other modifications have also been reported, for instance, aspartate isomerization and 
racemization, which both have been shown to enhance peptide aggregation and fibril 
formation [51,52]. Interestingly, these modifications are not found in significant amounts in 
AD animal model Aβ pathology [53]. The effect of these modifications on soluble oligomer 
formation in vitro or in vivo has not been established. 
 
1.2.3 Importance to study Aβ oligomers 
 
In conclusion, it is important to study the assembly and toxicity mechanism of Aβ oligomers 
because: i) compared with fibrils, oligomeric Aβ are much smaller and more soluble which 
can readily diffuse through the brain parenchyma and induce synaptic dysfunction and 
memory loss. ii) As discussed in Section 1.6, the aggregation of Aβ is the early event in AD 
pathologic process, and it triggers the downstream tau pathology, which is better correlated 
with dementia. Also, Aβ oligomers treatment of cells causes intracellular tau to misfold.[54]. 
iii) Biological Aβ oligomers with a high degree of heterogeneity have been described as 
various assembly forms with different sizes and structure, resulting in different neuronal 
toxicities. iv) as mentioned in Section 1.5, the misfolded protein in other neurodegenerative 
disease such as PD and HD also can form small oligomeric assemblies with similar amyloid 
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structural feature as Aβ oligomers, suggesting that they could share a common mechanism of 
toxicity, despite their different amino acid sequence. Therefore the study of Aβ oligomers 
may translate to other misfolded protein oligomers might aid in their diagnosis and 
therapeutic treatment. 
 
1.3 How do oligomers impair memory? 
 
As a classical cellular model that underlies learning and memory as well as synaptic plasticity, 
long-term potentiation (LTP) is under intensive study. LTP and long-term depression (LTD) 
are complementary cellular models of learning and memory that constitute an attractive 
means of detecting perturbations of synaptic functioning in the absence of overt neuronal 
death [55]. 
 
Reports from numerous laboratories have now documented that both synthetic soluble and 
naturally secreted Aβ oligomers such as ADDLs can inhibit hippocampal LTP and disrupt 
memory function, in the absence of amyloid fibrils. But only a few studies have examined the 
impact of Aβ on LTD. A detailed study demonstrates that Aβ oligomers interfere with 
synaptic plasticity by blocking both tetanus-induced LTP and the reversal of LTD but 
completely sparing low-frequency LTD in rat dentate gyrus [55].  
  
The mechanisms of soluble Aβ oligomer formation in vivo and how they interact with 
neuronal cells leading to synaptic dysfunction and memory loss still remains unclear. The 
production of Aβ can depress synaptic transmission and the level of Aβ is correlated with 
synaptic activity in vivo in a transgenic mouse model [56,57]. Since an initial report of 
neuronal surface binding of soluble Aβ oligomers [3], subsequent observations have reported 
specific binding  of  synthetic and  biological oligomers to neuronal synaptic regions in  
hippocampus and cerebral cortex [39,40]. Both receptor binding and membrane 
permeabilization mechanisms have been studied (Figure 1.3).  
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Figure 1.3. Toxicity mechanisms of soluble Aβ oligomers.                                                                                
a, receptor-mediated binding; b, pore-forming permeabilization.  
 
1.3.1 Receptor-mediated binding mechanisms 
  
Formation of soluble Aβ oligomers in vivo can be induced by gangliosides such as GM1 
located on the membrane [58] and extracellular soluble proteins such as αB-crystallin and 
ApoJ. A variety of cell membrane-associated receptors have been reported to bind soluble Aβ 
oligomers, including nerve growth factor receptor (NGF-R), N-methyl-d-aspartate 
(NMDA)-type glutamate receptor (NMDA-R), insulin receptor, Frizzled receptor, and prion 
protein (PrPC). The interaction between peptide and receptors requires peptide aggregation, 
and is not sequence specific or stereospecific [17]. 
 
Compelling evidence from Yamamoto et al. demonstrates that the globular Aβ oligomers are 
formed rapidly in the presence of GM1 gangliosides and bind with NGF receptor, triggers the 
activation of apoptotic signaling and induces neuronal cell death [58]. Binding of ADDLs 
influences signaling pathways downstream of NMDA-type glutamate receptor on synaptic 
plasma membranes, causing neuronal damage through NMDA-R-dependent calcium influx, 
resulting in neuronal oxidative stress and synapse loss [59,60]. ADDLs can interfere with 
insulin receptor function at the cell surface and block specific kinases required for long term 
potentiation (LTP) [61]. Frizzled receptor–mediated binding of ADDLs causes the inhibition 
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of Wnt protein signaling, which is associated with tau pathology [62]. Prion protein PrPC on 
the cell surface binds prefibrillar oligomers at nanomolar concentrations, leading to 
impairment of synaptic plasticity [63].   
 
1.3.2 Pore-forming permeabilization mechanisms 
 
There is another plausible mechanism for Aβ oligomer toxicity, pore-mediated 
permeabilization mechanisms, as proposed several years ago by Rojas and co-workers [64]. 
The cell membrane is destabilized by the Aβ oligomers, resulting in the formation of 
cation-selective membrane pores and dysregulation of ion homeostasis, such as Ca 2+ [65]. 
Arispe et al. in 1993 first reported the formation of calcium- and other cation- selective 
channels in bilayer membranes by Aβ oligomers [66] followed by the finding of the formation 
of amyloid pores on the cell surface from pathogenic mutations [67]. The mechanism of 
permeabilization was clarified by subsequent studies suggesting that regardless of sequence 
soluble amyloid oligomers increase bilayer conductance by altering the dielectric structure of 
the membrane, leading to a conformation-specific permeabilization of lipid bilayers [68,69]. 
Importantly, the conductance of lipid bilayers was not increased by fibrils or monomers, 
indicating that permeabilization is a specific property of amyloid oligomers related to 
oligomer structure. 
 
1.4 Review of recent studies of Aβ oligomers  
1.4.1 Detection and characterization of Aβ oligomers 
 
Recent techniques employed to study soluble Aβ oligomers mostly focus on, quantitative 
analysis of sizes of monomer and different oligomers, and on qualitative identification and 
characterization of oligomers. Real-time monitoring of the size changes of oligomers is 
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desired during testing for assembly modulatory compounds when Aβ oligomers are the main 
target in therapy strategy. Understanding the structure and conformation of Aβ as well as the 
assembly-disassembly mechanism may provide insight into anti-AD drug design therapeutic 
intervention.  
 
The early tools for diagnostic testing for amyloid fibrils in tissue, the birefringence of the 
histologic dye, Congo red and fluorescence of thioflavin T have been widely used to 
characterize Aβ assemblies in the later stages of aggregation into fibrils, but they are not 
applicable to the early assembly stages and suffer from low sensitivity [70,71]. A variety of 
other techniques have been employed in the study of aggregation of Aβ [72]. A widely used 
electrophoretic technique for the size analysis of Aβ oligomers is sodium dodecyl sulfate 
polyacrylamide gel separation (SDS -PAGE). Other techniques for studying assembly size 
distribution include photochemical cross-linking (PICUP) followed by SDS-PAGE, 
size-exclusion chromatography (SEC), analytical ultracentrifugation (AUC), dynamic light 
scattering (DLS), ion-mobility spectrometry–mass spectrometry (IMS–MS), and fluorescence 
correlation spectroscopy (FCS). Techniques including single-site enzyme-linked 
immunosorbent assay (ELISA) and dot blotting with oligomer-specific antibodies have been 
applied to detect Aβ oligomers. However, these last two methods do not provide size 
information. 
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Table 1.1. Summary and characterization of different types of oligomeric soluble Aβ 
 
 
 
Oligomers Type Characteristics Size MW Reference 
soluble dimers 
and trimers 
Natural secreted from 
human brain and 
amyloid plaque 
extraction; 
SDS-stable; block 
LTP in vitro  
 1-3 nm in 
height and 
5-10 nm in 
width/length 
~8kDa 
and 
~12kDa 
[42], [73] 
Aβ*56 Natural SDS-stable 
dodecamers 
correlated with 
memory loss in APP 
ransgenic Tg2576 
mice model 
 N/A 56kDa [43] 
Aβ-derived 
diffusible 
ligands 
(ADDLs) 
Synthetic Small soluble 
globular structures; 
bind to dendritic 
arbors of cultured 
neurons; disrupt 
LTP at very low 
concentration 
5 nm in 
diameter 
Mainly 
17 and 
22 kDa 
[40] 
annular Aβ 
oligomers 
Synthetic Doughnut-like 
structures, formed 
from mutant Aβ 
8-12 
nm(outer 
diameter)  
and 2.0-2.5 
nm (inner 
diameter) 
150–250 
kDa 
[74], [75] 
Amylospheroid 
(ASPDs) 
Synthetic spheroidal structures  
highly neurotoxic, 
off-pathway,  
10-15 nm in 
diameter 
~330kDa [76] 
protofibrils 
(PFs) 
Synthetic Intermediates of Aβ 
fibril formation; 
β-sheet structure: 
bind Congo red and 
Thioflavin T 
<150 nm in 
length and 
~5 nm in 
width 
>100kDa [41], [77] 
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1.4.2 Kinetics studies of Aβ assembly and dissociation   
 
The underlying kinetics of assembly and dissociation of soluble Aβ oligomers are currently 
not very well understood because oligomers are transient and heterogeneous, even though the 
nucleation-dependent polymerization model for fibril formation is generally accepted [78]. 
  
The assembly of pre-fibrillar oligomers formed during the aggregation of the SH3 domain of 
PI3 kinase was studied by single-molecule fluorescence two-color coincidence detection 
(TCCD) [79]. Fibrils are formed with the accumulation of pre-fibrillar oligomers whose 
stability increases with time. At the early stage of aggregation those maximally cytotoxic 
species are a heterogeneous ensemble of oligomers with a median size of 38±10 protein 
molecules per oligomer, similar to estimated critical size of small oligomeric “seed” of fibril 
formation in AD and PD. There is a pronounced change in stability between soluble 
oligomers and fibrils indicating a general mechanism of amyloid aggregation in which those 
oligomeric species undergo an internal conformational reorganization during nucleation phase 
of fibril formation. This result is in line with the process predicted by computer simulations 
which involves a reorganization process of oligomers driven by interchain hydrogen bonding 
interactions that induce nucleation of the cross-β structure [80]. 
  
Kinetic stability of Aβ oligomers was described in a recent study and the off-rate of Aβ 
monomers dissociating from protofibrils was determined in the presence of an engineered 
Aβ-binding protein ZAβ3, which blocks Aβ aggregation by selectively sequestering 
monomers. The dissociation of monomers from Aβ protofibrils follows monoexponential 
decay kinetics with a slow rate and high activation energy, which is consistent with a 
dissociation model of oligomers reported in the previous study with treatment of small 
molecular assembly inhibitors [81].  
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1.4.3 Single-molecule studies of Aβ oligomers   
  
Compared with traditional ensemble techniques, single molecule techniques provide a 
complementary method for quantification and qualification of Aβ oligomers. Advantages of 
the single molecule techniques include low concentration (~nanomolar), fast real-time 
monitoring, and individual particle resolution regardless of sample heterogeneity.  
 
Recently a single molecule study based on photobleaching of fluorescently labeled Aβ was 
developed to determine the number of monomers in an oligomer [82]. The number of 
monomers forming individual oligomers is equal to the number of photobleaching events 
from excited fluorophores present in that oligomer. Thus the size of oligomers could be 
determined from recorded number of photobleaching steps. By building up a histogram of the 
number of subunits in each photobleached oligomer, the whole oligomer size distribution was 
extracted and then analyzed by Monte Carlo simulations. Although this approach is only 
suitable for oligomers containing low numbers of monomers (such as hexamer), the result 
was in close agreement with the oligomer size distribution from HPLC size exclusion gel 
filtration. Single molecule step-wise photobleaching is a novel avenue to study the size 
distribution of small Aβ assembly ensembles with high heterogeneity.  
  
As one of the advanced single molecule techniques, FCS has been widely used for detection 
of diffusion of fluorescence labeled Aβ monomers and oligomers in aqueous systems. By 
detecting the fluorescence intensity fluctuations as each single dye-labeled particle passes 
through a well-defined confocal volume, FCS can provide the number of fluorescent particles 
and diffusion time, which relate to the concentration and size of the particles, respectively. In 
1998 Pitschke et al developed a method to study the seeded multimerization process using 
FCS, by adding fluorescent labeled synthetic Aβ(1-42) peptide to pre-existing aggregate “seed” 
in cerebrospinal fluid samples from Alzheimer‟s patients [83]. In contrast to cerebrospinal 
fluid control, only the AD-sample generated the high intensity fluorescent events from 
fluorescent labeled synthetic peptide bound to multimeric species suggesting that Aβ 
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multimers could potentially be a bio-marker for AD diagnosis. Almost at the same time 
Tjernberg et al. showed the utility of FCS for the study of the inhibition of Aβ polymerization 
in vitro by synthetic Aβ ligand LBMP1620 labeled with the fluorescent dye rhodamine [84]. 
The Aβ ligand could inhibit the polymerization process at early stages. In this thesis, the 
mechanism of Aβ assembly-disassembly will be explored by FCS at near physiological 
concentrations of Aβ(1-42) peptide. 
 
1.5 Mechanism study of Aβ1-42 assembly-disassembly at near physiological 
concentration 
1.5.1 Aβ1-42 and oligomerization 
   
In this thesis synthetic Aβ1-42 is used to form the main target Aβ oligomers, since they are 
the major species composing the deposited plaque in the brain [85] and Aβ oligomerization 
process is more facile with Aβ1-42 than with Aβ1-40 [74].  
 
Aβ oligomerization is closely related with enzymatic process and familial AD mutations. 
Since the second endoprotease, γ-secreatase in the enzymatic process cleaves at different sites 
which occur after amino acid 38, 40, 42. The resulting Aβs vary in length of polypeptide 
chain, as well as self-aggregating potential. The most biologically abundant Aβ peptide 
circulated in extracellular fluids like blood plasma and cerebrospinal fluid is Aβ 1-40 
(80%-90%). However, Aβ1-42 (5%-10%) oligomerizes much more readily than Aβ1-40 due 
to its highly hydrophobic C-terminus with two additional hydrophobic amino acid residues 
(alanine and isoleucine).  
 
The method of photo-induced crosslinking of unmodified proteins (PICUP) [86] has been 
used recently to covalently stabilize the early unstable intermediates of Aβ aggregation and to 
elucidate the size distribution of the early stages of Aβ1-40 and Aβ1-42 assembly, by 
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combining with SDS-PAGE and size exclusion chromatography (SEC). Aβ1-42 stepwise 
forms paranuclei (pentamer/hexamer) units that self-associate to form higher-order oligomers 
like early protofibrils whereas Aβ1-40, instead of paranuclei, produces a mixture of monomer, 
dimer, trimer, and tetramer [74]. This unique fundamental feature, paranucleus formation by 
Aβ1-42, provides an explanation for its strong correlation with AD.  
 
Familial AD mutations in the N-terminal and C-terminal regions of the Aβ peptide in APP 
and in PS1/ PS2 elevate the ratio of Aβ1-42/Aβ1-40, which inversely correlates with age of 
disease onset and directly with Aβ aggregation level. One recent study demonstrated that the 
mean age of familial AD onset in caused by PS1 mutations correlates inversely with the 
Aβ1-42/Aβ1-40 ratio (either increased Aβ1-42 production or reduced Aβ1-40 level) [87]. 
Furthermore, enhancement of Aβ1-40 production, but not Aβ1-42 reduces the deposition of 
Aβ1-42 in brain in a transgenic mouse model [85].  
  
1.5.2 Relationship of the concentration of synthetic Aβ peptide for oligomer formation in 
vitro to in vivo monomer concentrations  
 
Studies on Aβ oligomers have been conducted primarily with high concentrations of synthetic 
Aβ peptides, mainly Aβ1-40 and Aβ1-42, as a model for Aβ assemblies found in the brains of 
AD patients. Aβ oligomers have been prepared at different concentrations since the type of Aβ 
peptide, preparation conditions, buffer ions, and incubation time can lead to different critical 
concentrations for oligomer formation. Surface tension measurements followed by 
SDS-PAGE showed that Aβ1-36 residues or longer in water has a critical concentration of 
~25 μM below which only monomers and dimers are observed [19]. In the study of divalent 
metal ion interactions with Aβ oligomers, the oligomers were prepared by incubating a 
mixture of 60μM Aβ1-40 with 100 nM rhodamine-labeled Aβ1–40 in Hepes buffer for 48 hrs. 
The resultant size distribution analyzed by FCS included monomer and low molecular 
oligomers (1.2 to 3.0 nm) as well as larger oligomers (50 to 120 nm) [88]. In the PICUP 
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experiment in section 1.5.1 the paranuclei (pentamer/hexamer ) of Aβ1-42 were formed in a 1 
μM solution (in 20 mM sodium phosphate buffer, pH 7.4) [74], whereas a rapid equilibrium 
involving monomer, dimer, trimer, and tetramer for Aβ1-40 prior to further assembly was 
observed at a concentration of 20 μM [89].  
 
However, these high concentrations are not consistent with the physiological concentrations 
of amyloid-β peptide, typically nanomolar to sub-nanomolar in cerebrospinal fluid and 
plasma, similar to the concentration of naturally secreted Aβ by cultured cells. At these low 
concentrations, the assembly of the peptide into oligomers differ in the kinetics of formation 
and possibly also in structure [90]. 
 
In our study the Aβ1-42 oligomer solutions are prepared at the tens of nanomolar 
concentration by the preparation method used for the sandwich ELISA study by LeVine [91] , 
which make it possible to study the assembly-disassembly mechanisms of oligomers at near 
physiological peptide concentrations. According to LeVine‟s study, large oligomers with 
molecular weight of 220 kDa and higher by size exclusion chromatography can be formed 
from synthetic Aβ1-42 at a concentration of 1–20nM when diluted from dimethyl sulfoxide or 
1,1,1,3,3,3-hexafluoro-2-propanol. These oligomers are the same size as those observed by 
SEC of soluble extracts of AD brain and an AD pathology mouse model brain [7,92].  
 
1.5.3 Oligomers as therapeutic target 
 
The soluble Aβ oligomeric species are the principle focus of our study since they are the main 
toxic species in AD which cause early synaptic dysfunction and memory loss, and also trigger 
downstream tau pathology. Both natural and synthetic oligomers have been studied for their 
disassembly mechanism. Cell culture-produced biological Aβ oligomers and oligomers 
isolated from transgenic mice are considerably more stable to disassembly than those formed 
from synthetic peptide [43]. In vitro incubation of synthetic Aβ (1–42) peptide produces a 
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series of rapidly exchanging unstable low-n oligomers culminating in a proportion of 
relatively stable 12–24-mers that can associate to higher order species. These soluble 
misfolded oligomers of the Alzheimer‟s Aβ peptide are significantly more toxic to neurons 
and other cell types than are monomers or fibrils [12]. 
  
People have been attempting to target oligomers directly and indirectly in many ways. Potent 
highly selective inhibitors of BACE and γ-secretase that can readily enter the brain lower the 
production of monomers as well as oligomers. Eli Lilly and Company tested the efficacy of a 
functional γ-secretase inhibitor, LY450139 in phase II trials [93]. Preclinically, this compound 
had already been shown to reduce the rate of formation of Aβ in vitro and in vivo. While this 
approach is effective at reducing Aβ production, disruption of these proteases which have 
many other substrates besides APP has the potential to cause side effects. 
 
Based on the discovery of a receptor-mediated toxicity mechanism, as introduced earlier, 
development of oligomer receptor antagonists is also a possibility. When the receptor is the 
target of the right type of small molecule antagonist, soluble Aβ oligomers effects could be 
reduced. This is likely to be complicated as effects on the interaction of the native ligand with 
its receptor must also be considered. Recently efforts have been made to target the 
neurotransmitter pathway mediated by the N-Methyl-D-aspartate (NMDA) receptor. 
Memantine, a low-moderate affinity uncompetitive NMDA receptor antagonist, has been 
approved by the U.S. Food and Drug Administration for treatment of moderate-to-severe AD 
in 2003 [94]. Interestingly, a recent study shows there is little evidence of any benefit in mild 
Alzheimer‟s disease [95]. 
 
One of the furthest advanced methods is reduction of Aβ monomer and oligomers by 
immunotherapy either passively with anti-Aβ antibodies or by active Aβ vaccination. Since 
Solomon et al. reported in 1996 in vitro epitope-dependent inhibition of Aβ fibrillation by 
monoclonal antibodies [96], one effective mechanism of immunotherapy was described by 
McLaurin et al. for antibodies selective for residues 4–10 of Aβ1-42 which blocked synthetic 
Aβ oligomerization and cytotoxicity [97]. The in vivo study of peripheral injection of an 
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oligomer-specific antibody normalized cognitive behavior and synaptic deficits in APP 
transgenic AD mice, providing direct support for the use of selective Aβ oligomer-binding 
antibodies to improve cognition in AD patients [98]. Moreover, endogenous antibodies that 
were raised by active Aβ vaccination also had the ability to neutralize oligomers and prevent 
the inhibition of LTP in vivo [99]. However, immunization also interferes with production of 
monomers which are thought to have a positive, modulatory effect on synaptic plasticity and 
memory in low concentrations [100]. Moreover, dosing in a phase II clinical immunization 
trial of AN-1792 Aβ vaccine was suspended when an encephalitis side effect was found in a 
subset of patients. There were no measureable effects on cognition even though much of the 
insoluble Aβ pathology was cleared [101]. The encephalitis side effect of the AN-1792 
immunization procedure has since been corrected and additional immunization trials are 
underway.  
 
An alternative directly therapeutic approach is blocking the assembly of soluble Aβ oligomers 
from monomer or dissociating the preformed oligomers. A number of drug discovery efforts 
involving high throughput screening of small-molecule libraries have led to the discovery of 
efficacious assembly inhibitors. The inhibitory effects of clioquinol and other 
8-hydroxyquinoline derivatives on Aβ assembly in vitro were identified with a single-site 
biotinylated Aβ1–42 oligomer assembly assay from the screening of the NINDS-Custom 
Collection of 1040 drugs and biologically active compounds [102]. Interestingly, the 
inhibition activity is not related to their chelating activity, even though clioquinol can chelate 
zinc and copper and inhibit aggregation caused by these metal ions. Prana Biotechnology is 
pursing therapeutic applications of this class of molecules.    
 
1. 5.4 Dissociation of oligomers with DHBA isomers and other compounds 
 
Dissociation of preformed oligomers by potent small molecules is a less often pursued 
therapeutic avenue as most literature assays are not configured to monitor this process. In our 
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study, a series of dihydroxybenzoic acid (DHBA) isomers as well as other dissociating 
compounds are used to study the disassembly mechanism of soluble Aβ(1-42) peptide 
oligomers. They were discovered using a dissociator screen of a small molecule structural 
diversity compound library [103]. Studies of the DHBA isomers with a biotin-avidin 
interaction-based ELISA assay coupled with size exclusion chromatography and PICUP, 
showed that the DHBA isomers have no effect on assembly, but a hydroxyl 
position-dependent ability to dissociate preformed oligomers. A model of the dissociation 
process was posited that these compounds progressively dissociate monomers from oligomers 
rather than fissioning oligomers into smaller intermediates, since intermediate size species 
were observed. However, the model is not very well defined because the oligomer detection 
method employed does not provide size determination. The single-site assay cannot 
distinguish large numbers of small oligomers from small numbers of relative larger oligomers 
if both of them have an identical number of exposed biotins. Oligomers with molecular 
weight below than 40-50 kDa are poorly detected by the single-site assay. In addition, large 
aggregates also might not be detected quantitatively since it is possible that a significant 
number of biotins are inaccessible due to oligomer shapes [104]. Therefore, a single-molecule 
detection method becomes a necessary tool here in order to provide an accurate quantification 
of numbers of oligomers of different sizes in a heterogeneous population. 
 
In this study, by using fluorescence correlation spectroscopy coupled with atomic force 
spectroscopy, we were able to not only measure the size distribution of amyloid-β oligomer 
sample over a wide range of sizes at physiological concentrations (~nM), but also to monitor 
the change of size and fraction of oligomers during the dissociation process in real time.  
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Chapter Two: Materials and Methods 
2.1 Experimental 
2.1.1 Chemicals and products 
 
The benzoic acid derivatives, Tween 20 (ultrapure), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 
trifluoroacetic acid (TFA), dimethyl sulfoxide (DMSO), tetramethylbenzidine, 
N,N-dimethylacetamide, bovine serum albumin (BSA, Fraction V), 30% w/w H2O2, silicon 
dioxide mesh (sand), polyethyleneglycol bisphenol A epichlorohydrin copolymer (PEG, 
15-20kDa), rhodamine110 (R110) (Abs/Em maxima = 496/520 nm), urea, and guanidine 
hydrochloride (GdnHCl) were purchased from Sigma-Aldrich (St. Louis, MO). Sephadex 
G-75 and G-100 (medium) were purchased from GE Healthcare. N-α-biotinyl-Aβ(1-42) and 
fluorescein-Aβ(1–42) (Abs/Em=494/521nm) were purchased from Anaspec (San Jose, CA). 
Monoclonal Aβ (unmodified and biotinylated) antibodies to the human sequence Aβ-peptide, 
4G8 (a.a. 17-24) were purchased from Covance Laboratories (Princeton, NJ). HRP-labeled 
streptavidin and HRP-goat antimouse secondary antibody were purchased from Rockland, Inc. 
(Gilbertsville, PA). NeutrAvidin (NA) was obtained from Pierce (Rockford, IL). High binding 
ELISA plates were obtained from Costar (Cambridge, MA). R-Phycoerythrin (Abs/Em 
maxima=546/578nm) was purchased from Invitrogen. Glass wool, 0.22μm syringe filter, 
Amicon ultra-15 centrifugal filter (50K cutoff) and phosphate buffered saline (PBS) 10x 
solution were purchased from Fisher Scientific (Waltham, MA) 9.9mm mica discs and 12mm 
metal specimen discs were obtained from Ted Pella (Redding, CA).  
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2.2 Sample Preparation 
2.2.1 ELISA screening assays 
2.2.1.1 Preparation of biotinyl-Aβ1-42 Oligomers 
1 μl of 1 mg/ml N-terminal biotinyl-Aβ1-42 peptide dissolved in 1,1,1,3,3,3-hexa- 
fluoro-2-propanol (HFIP) solution was added to 25 μl additional HFIP in a polypropylene (PP) 
tube. HFIP was then removed with a gentle stream of inert gas creating a thin film of 
biotinylated Aβ peptide formed at the bottom of the PP tube. This film was subsequently 
dissolved in the same volume of trifluoroacetic acid (TFA) and then dried using an inert gas 
stream after incubation at room temperature for 10 min. An additional 25 μl of HFIP was 
added to redissolve the peptide film followed by HFIP removal along with any residual TFA 
using an inert gas stream. The treatment combined with HFIP and neat TFA aids in keeping 
Aβ1-42 monomeric by breaking up any “seeds” or small aggregates formed during storage. 
70 μl of dimethyl sulfoxide (DMSO) was then added to dissolve the peptide film and after 10 
min this 70 μl of 3 μM random coil peptide in DMSO was diluted 100-fold into 
oligomer-forming buffer (OFB = 50 mM sodium phosphate, 150 mM sodium chloride, pH 7.5) 
in a polypropylene container. After 30 min at room temperature, 70 μl of OFB containing 10% 
v/v Tween 20 was added to stop the assembly reaction and stabilize the Aβ1-42 oligomers. 
This 30 nM mixed monomer–oligomer solution was then either used immediately or frozen in 
aliquots at -75 °C for further use within 6 months. 
2.2.1.2 Sephadex G-100 size exclusion chromatography (SEC) 
A 10-ml pipette column was packed with Sephadex G-100 beads in oligomer-forming buffer 
(OFB) over a layer of sand and glass wool. The column was then equilibrated with OFB 
containing 0.1% Tween 20 filtered through 0.22 μm-pore-size filter. 250 μl of the mixture of 
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oligomeric and monomeric Aβ1-42 peptide solution was layered on the top of the column and 
eluted with OFB+0.1% Tween 20. 400 μl fractions were collected into a 96-well 
polypropylene plate (Costar) after the first 3 ml of void volume had been discarded. Collected 
fractions were frozen at −20°C for detection of oligomers as well as total Aβ peptide by 
ELISA.  
 
2.2.1.3 Preparation of NeutrAvidin-coated plate 
 
A 96-well ELISA plate was coated on the bottom of each well with 50 μl of 1 μg/ml 
NeutrAvidin™ (NA) in 10mM sodium phosphate (pH7.5), sealed with adhesive film, and 
stored at 4 oC overnight. Before use, the plate was blocked for 2 hours at room temperature by 
adding 200μl OFB containing 0.1% v/v Tween 20 to each well.  
 
2.2.1.4 Sandwich biotin–avidin assay for Aβ1-42 oligomers   
 
Aβ oligomers were assayed by biotin-avidin based interaction, which is less expensive than 
using antibodies and highly specific for recognition of oligomers [104]. As shown in Figure 
2.1, NA immobilized on the plate surface captures both biotin-labeled monomers and 
oligomers. Only oligomers with exposed biotin are detected by HRP-labeled streptavidin 
(SA-HRP) allowing for the direct quantification of oligomers in the presence of monomeric 
peptide. 
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Figure 2.1. Configuration of single-site biotin–avidin assay for Aβ1-42 oligomers. a, 
Chemical structure of N-α-biotinyl-Aβ(1-42); b, NeutrAvidin™ (red) was immobilized on the 
surface of the plate to capture both biotin- labeled monomer and oligomer through the 
biotin-avidin interaction. The captured monomer has a single biotin that since it is bound to 
NA is unavailable to interact with HRP-labeled streptavidin to generate a signal. The oligomer 
can be detected by SA–HRP because it contains uncomplexed biotins. 
 
 
 
The blocking solution was removed from the plate and 50 μl of each fraction eluted from 
Sephadex G-100 SEC was placed into each well of the NA-coated plate, the plate sealed, and 
incubated for 2 h at room temperature with shaking at 150 rpm. The plate was washed three 
times with 200 μl per well TBST (TBST = 20 mM Tris–HCl, 34 mM NaCl, pH 7.5, 0.1% 
Tween 20) with a Biotek ELx50 automated plate washer. To each well 50 μl of 1:20,000 SA–
HRP in OFB containing 0.1% v/v Tween 20 was added. The plate was sealed, and incubated 
for 1 h at room temperature with shaking at 150 rpm. After incubation, the same washing 
steps were repeated and 100 μl tetramethylbenzidine (TMB)/H2O2 substrate solution was 
added [105]. After 5-10 min the reaction was stopped by adding 100 μl of 1% v/v sulfuric 
acid. The optical density (OD) of the solution in the wells which is proportional to the number 
of immobilized oligomers was measured at 450 nm using a Biotek Synergy HT plate reader. 
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2.2.1.5 Sandwich ELISA for total Aβ1-42 (monomer + oligomer)   
 
For the total Aβ1-42 peptide assay, an NA-coated plate was used to capture biotinylated 
monomers and oligomers. The mouse monoclonal antibody, 4G8 which binds at a different 
site (Aβ residues 17-24), than the N-terminal biotin is added to bind to both monomers and 
oligomers. The bound 4G8 antibody is detected by HRP-goat anti-mouse secondary antibody 
(GAM–HRP) [104]. This total monomer + oligomer ELISA assay is depicted in Figure 2.2. 
 
Similar to the oligomer assay, 50 μl of the sample fractions were added to each well of the 
NA-coated plate for total peptide assay, and incubated at room temperature for 2 h shaking at 
150 rpm, and then washed three times. Wells were sequentially incubated for 1 h shaking at 
room temperature after adding 50 μl of 0.5 μg/ml 4G8 monoclonal antibody in OFB 
containing 0.1% Tween 20 and 2 mg/ml bovine serum albumin (BSA). Following washing, 
50μl of 1:10,000 GAM–HRP in OFB – Tween-BSA was added, and the incubation was 
continued for 1 hr shaking at room temperature. The plate was washed and developed as for 
the oligomer assay. The activity of HRP was detected with TMB/H2O2 and the OD450 nm was 
determined with a plate reader thus determining the total monomer + oligomer concentration. 
Combined with the oligomer assay described in 2.2.1.4, these assays allow for direct 
quantification of the monomer and oligomer concentrations in each sample fraction. 
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Figure 2.2. Configuration of single-site antibody assay for total Aβ1-42. a, Localization of 
4G8 epitopes on the sequence of human Aβ(1-42). b, Binding to NA which was immobilized 
on the bottom of wells, biotin labeled monomer and oligomer were both recognized by 
antibody 4G8 to their 4G8 epitopes and the bound 4G8 antibody detected with GAM–HRP to 
generate a signal. 
2.2.2 Fluorescence correlation spectroscopy experiment 
2.2.2.1 Preparation of fluorescein-Aβ1-42 Oligomers 
9.1μl of 0.2mg/ml fluorescein labeled Aβ1-42 (Fl–Aβ) monomer was mixed with 5.1μl of 
1mg/ml wild type Aβ1-42 peptide into 25μL of HFIP, which was then removed with an inert 
gas stream. 500μl DMSO was added to dissolve the peptide film and the solution was 
vortexed every 5 min. After 15 min, the disaggregated peptide in DMSO was diluted 100-fold 
into 50ml OFB in a polypropylene tube and mixed thoroughly.  
After 30 min, 2.5 ml of 1 mg/ml polyethyleneglycol bisphenol A epichlorohydrin (PEG, 
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15-20 kDa) copolymer filtered by 0.22 μm-pore-size filter was then added to the oligomer 
forming solution to stop the assembly reaction. The solution was then concentrated 6-fold by 
centrifugal filtration through a 50kDa cutoff membrane at 2, 500 xg at 4 oC in a swinging 
bucket rotor. 250 μl of this concentrated mixture of oligomeric and monomeric peptide was 
applied to the 10 ml Sephadex G100 column prepared as described in Section 2.2.1.3 and 
eluted with OFB + 0.1% v/v Tween 20. 400 μL fractions were collected with a 96-well 
polypropylene plate. Fluorescence intensity of each well was read by a Biotek Synergy HT 
plate reader. The isolated monomers and oligomers fractions would be distinguished by the 
peaks in the fluorescence intensity profile and further confirmed by fluorescence correlation 
spectroscopy (FCS) measurement.  
 
The final volume of concentrated sample as well as the fraction of oligomers was determined 
to be proportional to the spin time. After concentration, residual monomer was washed 
through the filter by 2 ml OFB containing PEG15-20kDa, retaining the concentrated 
oligomers. In order to provide a sufficient number of oligomer „events‟ for FCS experiments 
over a range of concentrations of Fl-Aβ in the sample, we concentrated our stock 
concentration of oligomers 100-fold. Concentrated solutions with high oligomer fractions 
were frozen in aliquots at -75 oC and diluted to appropriate concentrations for measurement 
by FCS. 
 
2.2.2.2 PEG effect on concentration of Fl–Aβ oligomers solution 
   
Oligomer solutions were prepared with and without PEG 15-20kDa following the same 
procedure described in Section 2.2.2.1 to determine the effect of PEG on oligomer formation. 
After concentration, final solutions were adjusted to a final volume of 500μl. After 30-fold 
dilution into phosphate buffered saline (PBS, 137 mM NaCl, 2.7mM KCl, 11.9mM phosphate 
buffer, pH7.4), 300μl of each sample was placed in a well of an 8-well NUNC chamber slide 
for FCS measurements.  
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2.2.2.3 Time course of FL-Aβ1-42 oligomer dissociation by FCS 
 
The mixed oligomer-monomer FL-Aβ1-42 sample was diluted 30-fold from the concentrated 
oligomer stock solution into phosphate buffered saline (PBS) pH 7.4 and 300 μl pipetted into 
each sample chamber by. A series of DHBA isomers, which were effective oligomer 
dissociators previously determined by LeVine [103], were weighed and dissolved in Milli-Q 
water to make stock solutions 1mM, 0.5mM and 0.25mM, and then 3μl of each solution was 
added into individual 300μl diluted Aβ1-42 samples producing a final concentration of DHBA 
10μM, 5μM and 2.5μM. Each chamber was measured by FCS at room temperature over time.  
 
In addition, the effect of solvent (DMSO), a surfactant (Tween 20) and protein denaturants 
(urea and guanidine hydrochloride) on Aβ oligomer stabilities was also examined by FCS and 
compared to the DHBA isomers. 
2.2.3Atomic Force Microscopy (AFM)  
2.2.3.1 Preparation of sample for AFM 
 
9.9 mm diameter mica discs were immobilized on 12 mm metal specimen discs with double–
backed tape. For AFM experiments, a piece of single--sided Scotch tape was placed on the top 
of the mica surface and then gently peeled off to create a smooth, freshly cleaved surface 
suitable for force microscopy. 10 μl of the diluted Aβ samples solutions were deposited on the 
freshly cleaved mica and incubated for 15 minutes at room temperature. Samples were then 
rinsed with Milli-Q water for 10 seconds and gently blown dry under a stream of N2 gas. 
When ready for imaging, each specimen disc was placed on top of the piezoelectric scanner 
of the AFM instrument.  
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2.3 Instrumentation 
2.3.1 Fluorescence Correlation Spectroscopy 
 
All FCS measurements were performed on an Alba FCS system (ISS) at room temperature. A 
Nikon Ti-U Epifluorescence microscope in an epi-illumination configuration with an 
apochromatic 60× numerical aperture 1.2 water immersion objective provided the focusing 
optics. The fluorescent particles were excited with the continuous wave 488 nm line from a 
solid-state diode laser and the emitted radiation was isolated by a 530 nm dichroic long pass 
filter. The intensity fluctuations were detected by an H7422-40 PMT detector (Hamamatsu) 
and the measured autocorrelation functions were analyzed and fit using a one or two 
component model with VistaVision software.   
 
2.3.1.1 Theory of FCS 
 
A well-defined observation volume typically on the order of femtoliters, defined as the 
“confocal volume”, is formed by the laser passing through dichromic mirrors and objective of 
a confocal microscope. The lateral and axial dimensions, ω and z, for the confocal volume we 
used were determined to be approximately 3μm and 0.3μm, respectively (Figure 2.3a).  The 
illumination volume is approximated with a three-dimensional Gaussian function and the 
calculated confocal volume is ~0.5 fL and the effective volume which is larger than the 
confocal volume by a factor of 23/2, is equal to 4 fL [106]. When Brownian motion carries 
fluorescently labeled molecules through the confocal volume , the fluorescent dye is excited 
and emits fluorescence intensity F(t) detected using a photomultiplier tube (PMT) (Figure 
2.3b). Fluctuations in the time correlation of the fluorescent signal is auto-correlated using 
VISTA software to calculate an autocorrelation curve [107]. The autocorrelation function G(τ) 
can be fit using model-dependent equations to reveal the mechanism and kinetics of the 
diffusion of the fluorescent particles; including the average number of fluorescent particles 
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and the average time that the particle takes to diffuse through the confocal volume. In this 
way, not only the size of the particles, but also the number concentration of particles can be 
determined by FCS [108]. Importantly, the relative fluctuations become smaller with 
increasing numbers of measured particles present in the confocal volume, so it is necessary to 
minimize the average number of particles for such an extremely small confocal volume. 
Therefore, an ideal working concentration for FCS measurement is one particle in the focal 
volume at a time, which typically results in solution concentrations of the order of nanomolar 
or lower for reliable fluctuation analysis [109]. 
 
 
 
 
Figure 2.3. Confocal setup for FCS detection. Reprinted from reference: S.T. Hess, S. Huang, 
A.A. Heikal, W.W. Webb, Biological and chemical applications of fluorescence correlation 
spectroscopy: a review, Biochemistry 41 (2002) 697-705. 
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2.3.1.2 FCS data evaluation 
 
FCS measures the temporal fluctuation in the fluorescence signal from the excited molecules 
in the confocal volume. The normalized autocorrelation function G(τ) of the intensity 
fluctuation δF(t) of the signal F(t) is defined as  
 
𝐺( ) =  
〈 𝐹(𝑡)  𝐹(𝑡+ )〉 
〈𝐹(𝑡)〉2
                                         (1) 
  
with 
 
  ( ) =  ( )  〈 ( )〉                            (2) 
 
where δF (t) is the deviation of the intensity fluctuation [110]. Typically the illumination 
volume is approximated as a three-dimensional Gaussian function with lateral and axial 
dimensions, ω and z resulting in a 3D autocorrelation function of:  
 
      
 
where N is the average number of fluorescent particles and xi is the fraction of particles with 
translational diffusion time τD [111,112]. Hence, the diffusion coefficient, D of particles can 
be determined by the beam waist, ω from the calibration with standard and τD, which 
describes the dwell time i.e. the average time particles remain in the confocal volume [110]. 
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In this study one-component as well as two-component systems were calculated and 
compared to mimic the monomeric Aβ solution and the mixed monomer-oligomer solution 
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with the assumption that both monomer and oligomer are, on average, spherical particles with 
distinct diffusion times. 
 
For identical fluorescent particles undergoing ideal Brownian diffusion, dynamic information 
can be determined from the intensity fluctuations by means of a one component fit to the time 
autocorrelation given by  
 
 
      
 
If the system contains two diffusing species with sufficient hydrodynamic radii differences 
(e.g. a mixture of monomeric and oligomeric Fl-Aβ peptide), a two-component fit to the time 
auto-correlation can be used given by 
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where x1 represents the fraction of the monomeric Fl-Aβ with diffusion time τ1, and x2 
represents the fraction of the oligomeric Fl-Aβ with diffusion time τ2. x1 and x2 are dependent 
on quantum yield and average numbers of labeled Aβ species. While the quantum yield of 
oligomers and monomers are different (fluorescein-labeled oligomers are partially quenched) 
this does not affect this analysis since only the numbers of particles are being considered. 
Using equations (4) and (6), the diffusion coefficient, concentration and fraction of Fl-Aβ 
oligomers and monomers can be obtained from autocorrelation analysis. One limitation in 
single color FCS is there is a resolution limit for two-component systems as to the size 
differences required for meaningful data analysis. A resolution study of FCS measurement in 
1999 [113] revealed that the distinction between two different molecular species depends 
strongly on their differences in size, brightness and concentration. In order to be distinguished, 
this study estimated that the diffusion times of two components must differ by at least a factor 
of 1.6 (i.e., a factor of ~4 difference in hydrodynamic volume for spherical particles). 
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One important assumption in this work is that both the Aβ peptide monomer and oligomer are 
spherical particles with constant diffusion coefficient or sizes over the time scale of the FCS 
measurement. Hydrodynamic radii rh of each species can be calculated with the 
experimentally determined diffusion coefficient D by Stoke-Einstein equation:  
 
  =
  ∙  
    
                                                                             ( ) 
 
where kB is the Boltzman constant, T is the absolute temperature and η is the solvent viscosity. 
From this equation it is readily seen that the hydrodynamic radius, rh of the particle is 
inversely proportional to the diffusion coefficient, D. 
 
2.3.1.3  Optimization of measurement  
 
300 μl of the samples were placed in an 8-well Laboratory-Tek chamber slide (Nalgene Nunc 
International). Three different concentrations, 2.5 nM, 5 nM and 10 nM of free rhodamine 110 
(with known diffusion coefficient, D = 430 μm2s-1) were used for calibrating z and ω, which 
are the axial and radial dimensions of confocal volume with the sampling time of 30 seconds 
in each measurement. Since the peptide was labeled with fluorescein, PBS was used as 
solvent to control ionization of the dye. Different sampling times and laser intensities were 
used for optimization of measurement conditions. In this study, 100 nM FL-Aβ1-42 sample 
(Abs/Em=494/521nm) was measured by FCS with 60% laser intensity and a short 
measurement time of 1min was used to minimize complications arising from photobleaching.  
 
2.3.2 Atomic Force Microscopy 
 
Aβ amyloid samples were characterized by a Park systems XE-70 atomic force microscope. 
All measurements were conducted in tapping mode with ultrasharp silicon cantilevers 
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NSC14/AIBS (MikroMasch), which contained a reflective aluminum backside coating and tip 
radius of ~10 nm. The typical resonant frequency of these NSC14/AIBS cantilevers was ~160 
kHz with a force constant of 5.7 N/m. The Super Luminescence Diode (SLD) is used as the 
source for the 830nm laser. A scan size of up to 10 µm x 10 µm can be obtained by an X-Y 
scanner and a separate Z scanner with the XEP Software. 
 
2.3.2.1 Theory of AFM 
 
AFM uses a sensitive cantilever with a sharp tip to measure samples adsorbed on an 
atomically smooth surface [114]. When the AFM tip is scanning a surface, the cantilever 
bends due to forces between the tip and the sample surface which is dependent on the distance 
between them. A laser beam is aimed at the back of the cantilever and is reflected to a 
four-segment Position Sensitive Photo Detector (PSPD). The tube-shaped piezo scanner 
located under the sample monitors the movement of the sample in the horizontal direction by 
X-Y scan control and vertical direction controlled by the feedback loop. The measured 
cantilever deflections, containing the information of three dimensional shapes as well as the 
friction of the sample surface, allow a computer to generate an image of surface topography. 
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Figure 2.4. Schematic diagram of conventional AFM‟s working principle.  
Reprinted from reference: Park Systems Corp XE 70 User‟s Manual (2009)10. 
 
 
2.3.2.1.1 Tapping mode imaging for Aβ peptide 
 
There are two working modes in AFM: contact mode and tapping mode. During the contact 
mode scanning, a tip slides over the sample surface and is always in contact with the sample 
surface. Contact mode is especially useful for providing a high resolution for hard materials. 
The bend of the cantilever in the Y direction provides height information, and the distortion of 
the cantilever in the horizontal directions is indicative of the friction of the surface. However, 
the sliding of the tip may easily scrape the sample surface, especially for soft biological 
molecules.  
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Normally tapping mode is used for soft materials, like Aβ peptide [40]. In tapping mode, the 
cantilever is oscillated in a direction normal to the sample with constant oscillation amplitude 
associated with a feedback loop resulting in only intermittent contact with the surface [115]. 
Thus tapping mode avoids dragging the tip over the surface and protects the soft sample from 
tip damage. As shown in Figure 2.5, the amplitude of the oscillating tip decreases due to the 
repulsive force between the tip and the surface when it is scanning a higher surface region, e.g. 
oligomer adsorbed on the mica surface. Controlled by the feedback loop, a complementary 
voltage is applied to the Z scanner to lower down the sample in order to recover the amplitude 
so that the height information can be obtained from the voltage. Therefore, the topography 
images of the scanned surface can be acquired integrated with the lateral positioning 
information [116]. 
 
 
 
 
Figure 2.5. Schematic representation of detection of height in tapping mode. The oscillation 
amplitude of the cantilever decreases once the tip contacts a higher surface, e.g. oligomer 
peptide adsorbed on the mica surface. 
 
Moreover, the interaction between the tip and the surface are very dependent on the moduli of 
the materials involved. When a tip interacts with a surface of different stiffness a phase shift 
occurs. The phase of the drive signal is compared with the phase of the cantilever response 
signal on the PSPD so that it is possible to distinguish between different materials by 
comparing the surface features from phase images, which might be barely visible in height or 
amplitude images [117]. 
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Chapter Three: Results and Discussion  
3.1 Detection of Aβ1-42 oligomers assembly 
3.1.1 Fluorescence burst caused by Aβ1-42 assemblies 
 
Monomeric Aβ1-42 dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and treated with 
neat trifluoroacetic acid to disrupt “seeds” and small aggregates, changes during the assembly 
process from random coil peptides into a mixture of monomers and oligomers following 
dilution from dimethyl sulfoxide (DMSO) into phosphate salt-rich oligomer forming buffer 
(OFB). This sample preparation method is a consistent way to achieve oligomeric Aβ1-42 
with a total peptide concentration at biologically relevant (nanomolar) levels. The minimal 
concentration of total peptide for forming oligomers can be as low as 10 ng/ml (2.25nM) at 
room temperature as detected by an oligomer-specific single-site antibody assay [91]. 
 
For ELISA assay, Tween 20, a commonly used agent in ELISA assays to reduce background 
binding of antibodies, was added to block further aggregation assembly. For fluorescence 
correlation spectroscopy (FCS) measurements, PEG15-20kDa was used to inhibit aggregation 
as well as to block membrane adsorption during concentration of Aβ oligomers to obtain 
sufficient fluorescence intensity for oligomer detection in a reasonable time frame. Tween 20 
forms micelles that are larger than 50kDa, so PEG15-20kDa was substituted to avoid 
concentrating the detergent. Figure 3.1 shows the fluorescence intensity of non-aggregated 
and aggregated fluorescein-Aβ1-42 solutions. Aβ1-42 oligomer-containing solutions display 
large fluorescence peaks in the raw data as shown in Figure 3.1b that are absent in monomer 
only solutions (Figure 3.1a). More bursts appear in the intensity traces when oligomer 
samples are concentrated by centrifugal filtration in the presence of PEG15-20kDa. 
 
41 
 
 
 
Figure 3.1. Fluorescence intensity traces (photon counts vs time (s)) of non-aggregated and 
aggregated Aβ1-42. Aβ oligomer samples were prepared by dissolving a mixture of the 
N-terminal fluorescein-labeled Aβ1-42 with wild type Aβ1-42 (1:4 mole/mole) in DMSO, 
before diluting in OFB. PEG15-20kDa was added after oligomer formation to prevent further 
assembly and to protect against peptide adsorption to the 50kDa m.w. cutoff filtration 
membrane used to separate oligomers from monomers and to concentrate the oligomers. (a) 
monomeric Aβ1-42 in the flow through of the centrifugal filtration; (b) the mixture of Aβ 
monomers and oligomers prepared after centrifugal concentration in the presence of 
PEG15-20kDa. 
 
 
3.1.2 Size study of Aβ1-42 monomers and oligomers 
3.1.2.1 Two-component fitting model 
  
Unlike the monomeric Aβ sample (Figure 3.2a), the aggregated Aβ1-42 sample has an 
autocorrelation curve which cannot be well described with a one-component fit (red curve) 
given by equation 5 in the methods section in Chapter 2 . The blue curve is the result from a 
two-component fit (equation 6) described in the methods section. Here, we have modeled the 
data using a two-component fit where the fast component is fixed as the diffusion coefficient 
of monomeric Aβ1-42 and the slow component is allowed to vary. This approach results in 
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much better fitting than the one-component fit as shown in Figure 3.2b. The goodness 
 
 
 
Figure 3.2. Fluorescence autocorrelation curves fit using one- and two-component fitting 
models for non-aggregated and aggregated Aβ1-42. (a) monomeric Aβ1-42 is well-described 
using a one-component fit shown in red; (b) mixed Aβ1-42 monomers and oligomers 
solutions are poorly described by a one-component fit (red curve) but are well-described with 
a two-component fitting (blue curve) where the diffusion coefficient for monomeric Aβ1-42 is 
fixed and another diffusion coefficient for a slower component describing the oligomeric 
fraction is allowed to vary. χ2 (red curve) =0.340, χ
2 (blue curve) =0.279.  
 
 
of the selected model can also be checked against the acquired data by minimization of the χ2 
(chi-square) function using a Marquardt-Levenberg minimization algorithm. The value of χ2 
is generated by FCS data analysis software, VistaVision. χ2 of the red curve from 
one-component fit, 0.340, is larger than χ2 of the blue curve from two-component fit, 0.279. It 
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is, therefore, feasible to determine the diffusion coefficient, D2 of oligomers as well as the 
fractions in the two-component fitting model with the D1 of monomers fixed, determined 
from the autocorrelation curve of the monomer sample. For example, D1 determined for 
monomer is 218 μm2/s, so D2 of oligomers can be determined from the blue autocorrelation 
function, which is 9 μm2/s with an oligomeric fraction of 77.6%. 
 
We established a test system to determine the ability of our FCS system to distinguish 
diffusion of two non-interacting molecules of different molecular weights. Two fluorescent 
molecules, Rhodamine 110 (R110) and R-Phycoerythrin (PE), had their diffusion coefficients 
measured individually by FCS. Our measured values, 430 μm2/s and 48 μm2/s respectively, 
were similar to reference values [118]. The PE and R110 were mixed in different ratios (5:1, 
3:1, 1:1, 1:3 and 1:5) and tested by FCS to verify the ability of FCS and our data analysis of 
the autocorrelation function to discern diffusion of two different-sized populations. The laser 
intensity applied was 60% and the sampling time was 5s in order to minimize the 
photobleaching effect on PE. The diffusion coefficients of R110 and PE were fixed for the 
analysis by the two-component fitting method. The fractions calculated for each probe from 
the fitting result were compared with the theoretical fractions due to mixing, are shown in 
Figure 3.3. Through statistical analysis with the chi square test, we calculate a p value (=0.9) 
much larger than 0.05 thus we cannot reject the hypothesis that there is no difference between 
observed fractions and theoretical fractions of two components at 0.05 significance level. 
Therefore, the experimentally determined fractions determined by FCS were consistent with 
the theoretical fractional mixture values of PE:R110 suggesting that the two-component 
fitting model was adequate to distinguish particles whose diffusion coefficients differ by 10 to 
20-fold. 
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Figure 3.3. Evaluation of two-component fitting method with PE and R110 for FCS. The blue 
bars represent fractions of R110 and the pink bars are fractions of PE. The unhatched columns 
represent the mixed fraction of the two molecules and the hatched columns are the 
corresponding fractions calculated from the autocorrelation plot fits which are consistent with 
the proportions prepared in the mixture. (Statistical analysis result: The p value from chi 
square test is equal to 0.9, which is much larger than the significant level, 0.05, so the null 
hypothesis cannot be rejected) 
 
3.1.2.2 Size characterization of Aβ1-42 monomers and oligomers 
 
The stock solution of mixed Aβ1-42 monomers and oligomers was concentrated from 50ml 
OFB to 0.5 ml by centrifugal concentration through a 50kDa cutoff membrane. This stock 
Aβ1-42 solution enriched in oligomers was then diluted 30-fold into PBS for FCS 
measurement. Since most monomeric Aβ was removed by the molecular filtration, the final 
total Aβ concentration is much closer to physiological concentrations of Aβ than the ~μM 
concentration used in most prior studies [86,88,89] . This method of concentration provided 
Aβ concentrations that permitted consistent size evaluation of oligomer and sufficient 
detectable fluorescence intensity and sufficient number of oligomer „events‟ for FCS 
experiments over a range of concentrations of Fl-Aβ in the sample. Autocorrelation curves 
can be obtained for various fluorescent species of different sizes. 
 PE:R110  5:1  ~5:1  3.1  ~3:1  1:1  ~1:1  1:3  ~1:3  1:5  ~ 1:5 
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Figure 3.4. Fluorescence correlation of fluorescence dye, monomeric and oligomeric 
amyloid-β. (a) normalized autocorrelation curves of (from left to right) fluorescein (black), 
Aβ monomers (blue), and mixed monomers and Aβ oligomers (red); (b) measurement of 
diffusion coefficients: DFluorescein = 412±10 μm
2/s, Dmonomer = 210±24 μm
2/s, Doligomer = 9±1 
μm2/s; (c) the corresponding hydrodynamic radii (rh) calculated using Stoke-Einstein relation: 
rh,Fluorescein = 0.56±0.02 n, mrh,monomer = 1.1±0.2 nm, rh,oligomer = 25.9±2.9 nm.  
 
 
With one-component and two-component fitting analysis of the normalized autocorrelation 
curves for fluorescein and fluorescein-labeled Aβ peptide, monomeric and oligomeric Aβ can 
be compared as shown in Figure 3.4a. With the assumption, described in Materials and 
Methods, that both the Aβ peptide monomers and oligomers are spherical particles with 
constant diffusion coefficient or sizes over the time scale of the FCS measurement, the 
translational diffusion coefficients (D) of each sample can be calculated from G(τ), and the 
hydrodynamic radii (rh) can be calculated by using Stoke-Einstein relation given in equation 7. 
Hydrodynamic radii of rh,fluorescein = 0.56 ± 0.02 nm, rh,monomer = 1.1 ± 0.1 nm, rh,oligomer = 25.9 ± 
2.9 nm were determined by FCS as shown in Figure 3.4b and 3.4c. The hydrodynamic radius 
of the standard dye molecule used here (Rhodamine 110) was previously published to be rh = 
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0.54 nm ± 0.04 nm [118]. Both D and rh values from our experiments are consistent with 
previously published data [119]. 
 
3.1.3 PEG effect on assembly of Fl–Aβ oligomers  
3.1.3.1 PEG effect on concentration of Fl–Aβ oligomers solution 
 
With the normal Aβ oligomer preparation method (dilution of Fl-Aβ + WT peptide from 
DMSO solution into OFB) only a small fraction of the Aβ is oligomeric in a 30nM sample. 
Because the proportion of oligomeric Aβ was small the observation time required for 
sufficient numbers of oligomers to diffuse through the fluorescence observation volume 
would be very long. Hence, an effective way to concentrate Aβ oligomers was devised for 
practical measurements of Aβ monomers and oligomers by FCS. A derivative of PEG, 
polyethyleneglycol bisphenol A epichlorohydrin copolymer (PEG, 15-20kDa) was coupled 
with centrifugal filtration through a 50kDa cutoff membrane to concentrate Aβ oligomers 
m.w. > 100,000 in OFB. PEG15-20kDa stops Fl–Aβ aggregation, and allows recovery of 
Aβ1-42 monomers and oligomers from a gel filtration column and keeps oligomers from 
binding to the filter material without itself being concentrated by the filter. 
 
To determine the effect of PEG 15-20kDa on centrifugal concentration of Fl–Aβ oligomers 
through the 50 kDa filter, two oligomer samples (concentrated no PEG; with PEG15-20kDa) 
were prepared and diluted in phosphate buffered saline buffer (PBS, 137 mM NaCl, 2.7mM 
KCl, 11.9mM phosphate buffer, pH7.4). By FCS, oligomers were only found when 
concentrating in the presence of PEG15-20kDa. The observed fluorescence intensities were 
extremely low for the oligomer sample concentrated without PEG15-20kDa revealing the fact 
that there were few fluorescein labeled species remaining in the sample after concentration 
(Table 3.1). Moreover, no FCS evidence was observed for the existence of oligomers in the 
flow-through of the concentrator in the presence or absence of PEG 15-20kDa due to leakage 
through the filter membrane. The fluorescence intensity of Fl-Aβ monomer in the 
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flow-through for non-PEG sample was also lower than that of PEG15-20kDa sample.  
 
Table 3.1. Average fluorescence intensity for monomer in the flow-through of centrifugal 
filtration and concentrated Fl-Aβ sample. Unit of average fluorescence intensity, counts per 
second. 
 
 
PEG15-20kDa Non-PEG 
Monomer in the flow-through ~1000 ~800 
concentrated Fl-Aβ oligomer solution ~2000 ~800 
 
 
These results suggest the oligomers concentrated without PEG stuck to the filter membrane 
during the centrifugal filtration. It appears that PEG15-20kDa with a bis-phenol A core to 
which is attached two different oxyethylene chains (Figure 3.5), has more favorable 
interactions with the amyloid peptide (or the filter) and is able to keep the peptide from 
adsorbing to the filter. 
 
 
 
Figure 3.5. Chemical structures of a bis-phenol A core used to synthesize PEG15-20kDa.  
 
 
 
3.1.3.2 PEG effect on the size of Fl–Aβ oligomers  
 
Here arises a concern of whether adding PEG and concentration affect the size of oligomers. 
Atomic force microscopy (AFM) provided the ability to evaluate the morphology and 
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apparent size of oligomers and monomers. As one of a family of scanning probe microscope 
types, AFM is an ideal tool to follow the early events of Aβ amyloid assembly on 
single-molecule scale and used in this study to confirm the FCS result because it is capable of 
directly visualizing and measuring the dimensions of small protein that are adsorbed on the 
substrate from aqueous solution. However, AFM will only detect material that adsorbs to the 
substrate. 
 
In order to study the effect of PEG15-20kDa on the size of Fl–Aβ oligomers, the concentrated 
Fl–Aβ oligomer sample was prepared with and without PEG15-20kDa and examined by AFM. 
The no PEG solution was obtained by direct dilution from DMSO to OFB with final total Aβ 
concentration of 100nM to avoid peptide being adsorbed on the filter membrane during 
centrifugal filtration. Fl–Aβ with PEG15-20kDa was diluted 30-fold from the stock solution 
as previously described and both solutions were immediately added to the mica surface for 
atomic force spectroscopy (AFM) measurement. The most accurate particle sizing is obtained 
by the height information recorded during tapping mode AFM. From the height analysis, we 
see that oligomers made without PEG were smaller than that made with PEG15-20kDa, and 
this difference matches with their hydrodynamic radii measurement by FCS.  
 
As shown in Figure 3.6, the result shows that the average height of non-PEG sample is around 
15nm which is much smaller than that of oligomer made with PEG15-20kDa (~45nm). The 
appearance of small particles with height of 2~3 nm, was observed in sample with 
PEG15-20kDa, while only a few can be found in the sample without PEG. In the phase 
images for samples formed with PEG15-20kDa , the observed oligomers appear to have a 
halo suggesting they might be covered with a different material with a modulus different than 
the Aβ peptide. Samples formed without PEG do not have this halo in the phase images. This 
data suggests that we may be observing the existence of a PEG coating in the PEG15-20kDa 
formed oligomers. To test this hypothesis, a control experiment was conducted by scanning 
the solvent containing the same concentration of PEG15-20kDa but without Fl–Aβ peptide 
and comparing the AFM images. As shown in Figure 3.7, only some ~3 nm particles were 
observed suggesting the thickness of PEG might interfere with the resolution of small peptide 
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like monomers/dimers in AFM. In addition, a halo as in the oligomeric Aβ PEG samples can 
be seen in the phase image, indicating the observation of PEG by AFM in both Aβ with PEG 
and PEG only sample. We conclude that the presence of PEG may affect both the ability to 
concentrate oligomers as well as their size. It is better to minimize the amount of PEG in the 
Aβ sample for AFM scanning in order to have a reliable definition of low-molecular-weight 
oligomers. The presence of PEG15-20kDa is also a concern in FCS experiments for 
determination of absolute diffusion coefficients of oligomers and monomers since the surface 
of Aβ is modified with PEG. However, in this study we are more focused on the relative 
change of sizes of oligomers in the presence and absence of assembly modulators and adding 
PEG15-20kDa is a necessary step to give us enough oligomers to detect by FCS diffusing 
through the observation volume in a short time.  
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Figure 3.6. AFM of Fl-Aβ oligomer sample prepared w PEG15-20kDa and w/o 
PEG15-20kDa sample. a and b are topography images of Aβ1-42 oligomer sample w 
PEG15-20kDa and c is its phase image. d, e, and f are the topography images and phase 
images at the same sizes for Aβ1-42 oligomer sample w/o PEG15-20kDa. (scale bars: 1μm 
for a and d; 400nm for b, c, e, and f). 
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Figure 3.7. AFM of PEG15-20kDa solution. a, topography image of PEG15-20kDa solution; 
b, the corresponding phase image. (scale bars, 400nm) 
 
 
3.2 Disassembly of oligomeric Fl–Aβ by small molecule dissociators of Aβ oligomers  
 
To prepare the Fl-Aβ oligomer samples for FCS measurement, the mixed Aβ monomers and 
oligomers in oligomer forming buffer were concentrated by centrifugal filtration with a 
50kDa cut off membrane in the presence of PEG15-20kDa and then stored in aliquots at -80 
oC. Concentrated Fl-Aβ sample with high oligomer fractions were diluted 30-fold into PBS at 
the time of FCS measurement for the study of disassembly mechanism.  
 
3.2.1 Kinetics of Aβ1-42 oligomer dissociation by DHBA isomers 
 
A series of dihydroxybenzoic acid (DHBA) isomers were used to study the disassembly 
mechanism of soluble Aβ peptide oligomers. These molecules were selected based on 
previously published results by LeVine and coworkers [103] which established their 
structure-dependent efficacy to dissociate or stabilize Aβ1-42 oligomers after screening a 
small molecule structural diversity compound library. A primary dissociation experiment was 
carried out for (1:4) FL-Aβ/WT-Aβ incubated with 10 μM of each of the six DHBA isomers 
[103] and the relative changes in oligomer fraction were determined by FCS at 0h, 3h and 6h 
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(Figure 3.8). The oligomer fraction was determined by two-component fits to the FCS 
autocorrelation curves as described earlier. Only three isomers, 2,5-, 2,3- and 3,4- DHBA 
(Figure 3.9) were found to cause significant decrease of initial oligomer percentages and 
cause oligomer dissociation to monomer. Also, the difference between fractions of oligomers 
remaining in the solution for each DHBA isomers at the same time point reveals a possible 
difference between their dissociation potencies. These results are in good agreement with 
previously published results comparing oligomer and monomer fraction by sandwich ELISA 
assays [103]. These three active DHBA isomers were used to conduct the time course study of 
the disassembly mechanism of oligomers by FCS. 
 
 
 
Figure 3.8. The percent of initial oligomers in the 100 nM Aβ oligomer solutions in the 
presence of all isomers of dihydroxybenzoic acid (DHBA) for incubation time of 0 h, 3 h and 
6 h (from left to right). The concentration of compound in the solution was 10 μM. 
 
 
 
 
 
Figure 3.9. Chemical structures of active DHBA isomers for Aβ assembly dissociation. 
 a, 2,3-DHBA; b, 2,5- DHBA; c, 3,4- DHBA. 
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The dissociating effect of 2,5-DHBA on oligomers is readily apparent from the increase of 
monomer fraction as shown in Figure 3.10. From this figure, we can observe two important 
kinetic phases; the intrinsic dissociation of oligomers and the compound-stimulated 
dissociation. The intrinsic dissociation of oligomer without any compound produced a single 
exponential decay; while the compound, 2,5-DHBA showed a concentration-dependent 
double-exponential decay behavior. The monomer fraction increases with increasing 
2,5-DHBA concentration at each time point. All the 2,5-DHBA curves can be fit either by 
fixing D1 of monomer as ~210 μm
2/s and letting the D2 vary or by fixing D1 ~210 μm
2/s and 
D2 ~9 μm
2/s (consistent with the FCS determined diffusion coefficient for monomer and 
oligomer respectively) resulting in similar monomer:oligomer fractions in both cases. Here 
the fraction of monomer grows over time at the expense of the fraction of oligomers. 
Surprisingly, the size of the remaining individual oligomers does not appear to change 
significantly over time. This data is consistent with a higher order dissociation process 
indicating that the dissociation mechanism is neither like fission of oligomers into 
intermediate size species, nor like dissociation of individual monomers from oligomers. 
 
 
Figure 3.10. Time course of Aβ1-42 oligomer dissociation in the presence of 2,5-DHBA. 
Each data point represents the fraction of monomers after incubation of 100 nM Aβ1-42 
(85% oligomers) for different times with a range of concentrations of 2,5-DHBA. No 
compound (open circle); 2.5 μM (closed inverted triangles), 5 μM (closed circles) and 10 
μM (closed squares) 2,5-DHBA.  
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The less potent and efficacious 2,3- and 3,4-DHBA isomers also demonstrated their potencies 
to induce dissociation. Similar to 2,5-DHBA, their autocorrelation curves G(τ) can be well 
described by a two component fit with fixed diffusion coefficients of D1 (~210 μm
2/s) and D2 
(~9 μm2/s). As shown in Figure 3.11, these two DHBA isomers can also stimulate a 
double-exponential decay, which can be distinguished from the mono-exponential decay of 
intrinsic dissociation of the oligomers.  
 
 
Figure 3.11. Time course of Aβ1-42 oligomer dissociation in the presence of (a) 2,3-and 
(b) 3,4-DHBA. Each data point represents the fractions of monomers after incubation of 
100 nM Aβ1-42 (85% oligomers) for different times with a range of concentrations of 
2,3- and 3,4-DHBA. No compound (open circle); 2.5 μM (closed inverted triangles), 5 
μM (closed circle) and 10 μM (closed squares) 2,3-and 3,4-DHBA.  
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3.2.2 Similar dissociation results from FCS and ELISA 
 
The different DHBA isomer effects on oligomers as measured by the FCS and ELISA 
methods may be compared when the fractions of oligomers remaining in the solution at 
different incubation time is extracted from each time course curve and normalized. Figure 
3.12a shows the relative potencies of these 2,3-, 2,5-, and 3,4-DHBA isomers at 10 μM 
throughout the time course of Aβ oligomer dissociation. Interestingly, the trend is consistent 
with results from a time course study  
 
 
Figure 3.12. Effect of DHBA isomers on the time course of Aβ1-42 oligomer dissociation – 
comparison of FCS and ELISA methods. No compound (closed circle); 2.5μM (closed 
diamond), 5μM(closed inverted triangles) and 10 μM (closed squares) 2,3-and 3,4-DHBA. (a) 
Each data point represents the fractions of initial oligomers in the solution after incubation of 
100nM Aβ1-42 (85% oligomers) for different times with 10 μM of 2,3- and 3,4-and 
2,5-DHBA; (b) The amount of oligomers remaining after incubation for different times with 
10μM of 2,3-, 2,5-, and 3,4-DHBA was determined by sandwich biotin–avidin assay with 2.8 
nM biotinyl-Aβ(1-42) (from LeVine, et.al. [103]).  
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with the same DHBA isomers by sandwich biotin–avidin assay (Figure 3.12b) reported 
previously by LeVine [103]. 2,5-DHBA had the greatest dissociation potency and efficacy 
among the three active isomers. Two dissociation phases were observed by both techniques 
giving the impression of a double exponential decay process. One is an intrinsic dissociation 
of oligomers in the absence of compound which can be fit by a mono-exponential function; 
and the other provides an additional decay for interaction with DHBA isomers.  
 
Importantly, there is no apparent size change of oligomers observed by FCS at any detection 
time during the dissociation process when reacted with DHBA isomers. This data is consistent 
with results in LeVine‟s previous study. No intermediates (<70kDa) of oligomers were 
detected by ELISA assay of SEC profiles at different times (0h, 2h, 5h and 8h) of dissociation 
caused by 2,5-DHBA.  
 
3.2.3 Higher-order dissociation model 
 
The fitting of correlation functions at different times with two fixed diffusion coefficients 
suggested there was no obvious change of size for oligomers during the dissociation process 
caused by DHBA isomers, which means the only two species detected in the solution were 
monomers and oligomers with constant sizes. One plausible hypothesis for the dissociation 
mechanism is that it is a higher-order dissociation process: a small molecule binds to an 
oligomer and stimulates its nearly instantaneous cooperative dissociation of oligomers into 
monomers. With the single-molecule level detection of freely diffusing species provided by 
FCS, the appearance of transient intermediates was not observed, consistent with a higher 
order cooperative dissociation process.  
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3.3 Vehicle (DMSO, Tween 20) effect on Aβ oligomer Disassembly   
3.3.1 Different fractions of oligomers obtained from FCS and ELISA measurement  
 
Size exclusion chromatography (SEC) is commonly utilized as a complementary method to 
study the size distribution of Aβ1-42 since there is a quantification caveat in the single site 
antibody assay that it is hard to distinguish between a large number of small oligomers and a 
small number of very large oligomers [120]. SEC separates particles based on their size 
(hydrodynamic radius); very large particles elute first in the void volume without penetrating 
the bead matrix while it takes longer for smaller molecules to enter and pass through the pores 
of the beads. Molecular weights of globular species by SEC can be calibrated in advance by 
comparing elution position to that of globular proteins of known sizes. 
 
250 µL of 200 nM mixed Fl-Aβ monomers and oligomers (FAM:WT=1:4) prepared after 
centrifugal concentration was applied on a 12 ml Sephadex G100 column and eluted with 
OFB + 0.1% Tween 20. The fluorescence intensity profile for the collected fractions (Figure 
3.13) showed two peaks distributed around Faction 5 and Fraction 23 indicating the position 
of fluorescein-labeled oligomers and monomers, respectively. Therefore, the 5 fractions 
centered around these two peaks was measured by FCS. Autocorrelation curves for fractions 
(5 ± 2 and 23 ± 2 nm), were consistent with isolated oligomer and monomer fractions, 
respectively. As shown in Figure 3.14, the curves for Fraction 23 and monomer in the 
filtration flow-through were identical and well described by a single component fit resulting 
in a diffusion time consistent with monomer. Fraction 5 was a mixture of oligomers and 
monomers and required a two-component fit to describe the autocorrelation function. The 
detected fraction of oligomers in Fraction 5, however, is only ~15%, which is different from 
the result obtained by our collaborator Dr. LeVine by re-running the pool of the void volume 
fractions from SEC containing oligomers on the Sephadex G100 SEC column again. 
Detecting total Aβ peptide the LeVine group saw very little monomer in the 
rechromatography (Figure 3.15). 
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Figure 3.13. Fluorescence intensity profile for the elution of 200nM Fl-Aβ oligomer sample 
from Sephadex G100 size exclusion chromatography. Two hundred fifty microliters of 200nM 
Fl-Aβ mixed oligomers and monomer were applied to the column. After discarding three 
pre-void volume fractions (0.4ml), of thirty additional fractions were collected covering the 
Sephadex G100 column total bed volume as described in Method and Materials.  
Figure 3.14. Fluorescence autocorrelation functions for the SEC pools (monomer and 
oligomer), monomer, and original 200 nM total Fl-Aβ sample. Monomers in the flow-through 
of the concentrator (closed circles), Fraction 23 (open squares), Fraction 5 (open triangles) 
and concentrated 200 nM Aβ solution (closed squares). 
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Figure 3.15. ELISA for total Aβ (6E10/bio4G8) of a re-run of Sephadex G100 void volume 
containing oligomers. There is maybe a hint of monomer around Fraction 15 but not as high 
as 85% monomer as reported by FCS. (made by Dr. LeVine) 
According to FCS, Fraction 5 eluting in the column void volume with OFB+0.1% v/v Tween 
20 should have a large fraction of oligomers. The autocorrelation fitting result from FCS 
shown in Figure 3.14, showed this sample to contain an even smaller fraction of oligomers 
(~15%) than the original concentrated total 200 nM Fl-Aβ mixtures (fraction of oligomers 
~60%). The column fraction 5 solution contained 0.1% Tween 20 while the 200 nM Fl-Aβ 
mixtures were prepared in the presence of 100 µg/ml PEG15-20kDa without Tween 20. This 
caused us to explore the effect of solution conditions on the dissociation of Aβ oligomers. We 
do not have a satisfactory explanation why the high molecular weight fraction from SEC 
contained such a large proportion of monomer when examined by FCS.   
3.3.2 Tween effect on Aβ oligomers disassembly 
The mild detergent Tween 20 has been found to stabilize and inhibit oligomer formation at the 
early stages of complexation [91]. However, by FCS we find that pre-formed oligomers 
concentrated in the presence of PEG15-20kDa dissociate in the presence of Tween 20. Three 
different concentrations, 0.001%, 0.01% and 0.1%, of Tween 20 v/v were studied. 0.1% v/v 
Tween 20 is commonly used in the ELISA assay as well as the SEC separation to avoid 
adsorption of peptide and stop further assembly. The time course of concentration-dependent 
Aβ dissociation as measured by FCS is shown in Figure 3.16. The effect of Tween 20 can be 
observed in the initial rate dependence on Tween 20 concentration of monomer appearance 
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derived from the tangent to the early time course (Figure 3.17). This half-maximal effective 
concentration, EC50, is approximately the critical micelle concentration of Tween 20 (~60 
μM). Interestingly, as an oligomer assembly inhibitor, Tween 20 has been shown to block 
oligomer formation with an EC50 between 0.1 and 0.5 μM [121], much lower than 60 μM. 
Thus, at low concentrations Tween 20 appears to act as an oligomer assembly inhibitor, but at 
high concentrations it can induce dissociation of oligomers. Moreover, comparison of the FCS 
data suggests that both Tween 20 and DHBA isomers dissociate through a cooperative 
dissociation mechanism.  
Figure 3.16. Time course of Aβ1-42 oligomer dissociation in the presence of Tween 20 over a 
range of concentrations. No Tween 20 (open circle); 0.001% (closed inverted triangles), 0.01% 
(closed circles), and 0.1% (closed squares) v/v Tween 20. 
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Figure 3.17. Initial rate of Aβ1-42 oligomer dissociation by Tween 20 at different 
concentrations.   
3.3.3 DMSO effect on Aβ oligomers disassembly 
Figure 3.18. Time course of Aβ1-42 oligomer dissociation in the presence of DMSO. No 
DMSO (open circle), 0.1% v/v (closed inverted triangles), 0.7% v/v (closed circles), and 3% 
v/v (closed squares) v/v DMSO. 
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Aβ oligomer stability to the solvent DMSO was also examined by FCS as the solvent has 
been shown to both inhibit assembly and stimulate Aβ oligomer dissociation. Figure 3.18 
shows that dissociation of Aβ1-42 oligomer is dependent on DMSO concentration. 0.1% v/v 
DMSO had little effect on dissociation and the curve was almost identical to the intrinsic 
dissociation curve (open circles). After adding 0.7% v/v DMSO the initial fraction of 
monomer at 0 h increased but the shape of the curve paralleled that of the intrinsic 
dissociation and 0.1% v/v DMSO curves. This suggests that these concentrations have similar 
dissociation rates. In the presence of 3% v/v DMSO the process became biexponential with 
time. The initial fraction of monomer increases, as well as the dissociation rate. For 
compound screening, DMSO is a convenient solvent capable of dissolving many compounds 
and minimizing their micelle/colloid formation which causes assay artifacts. Moreover, 
DMSO is used for monomer solubilization for Aβ oligomer preparation. From Figure 3.18, 
we see that while some DMSO is tolerated, too much DMSO (>3% v/v) severely affects the 
oligomer stability. Thus it is necessary to include a concentration control below 0.7% for 
DMSO. Similar to DHBA isomers as well as Tween 20, DMSO initiates the higher-order 
dissociation without generating detectable intermediate size oligomers. 
3.4 Dissociation of Aβ oligomers by denaturants 
Urea and guanidine hydrochloride (GdnHCl) are frequently used agents for destabilization of 
protein structure and denaturation of proteins. In this study, they were used to study 
self-quenching effects of fluorescein labelled oligomers by breaking up the oligomers 
completely into monomers and comparing the difference of the fluorescence counts compared 
to monomer:oligomer mixtures generated through exposure to Tween 20 and DMSO. In 
addition we found that these two denaturants favor a different dissociation mechanism than 
the higher-order cooperative dissociation previously discussed for Tween and the DHBA 
compounds. 
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3.4.1 Fitting models for Aβ oligomers exposed to urea and guanidine HCl denaturants 
 
FCS autocorrelation curves measured after exposing Aβ oligomers to urea and GdnHCl were 
well described by a two-component fit with the fast component fixed to the measured 
diffusion coefficient of monomer similar to the previously described results. Unlike the 
Tween 20, DMSO and DHBA results, however, the slower diffusing species was not well 
described by differing proportions of oligomeric particles with fixed diameter. During the 
time course of disassembly caused by denaturants, our data indicates that both the fraction of 
oligomers and their size change over time. Figure 3.19c shows the FCS autocorrelation curve 
measured for oligomer samples treated with 8 M urea after 1h. As shown by the black curve, 
this autocorrelation is not well described by a model where D1 and D2 were fixed to the initial 
monomer and oligomer diffusion coefficients as for the control (Figure 3.19a) and the χ2 for 
the black curve reached 0.558. As monomer size is fixed, we tried another model where we 
fixed D1 and allowed D2 to vary over time (blue curve, Fig 19c), which gave a larger D2
* 
value with smaller χ2, 0.313. This model accurately fits the autocorrelation curves consistent 
with a decrease in both size and number of oligomers as a function of time exposed to urea. 
Compared with to DMSO, for which the curve for 6 h DMSO treatment can still be described 
by fixing the same D1 and D2 as for control (Figure 3.19b), it is plausible that urea dissociates 
oligomers through a different dissociation mechanism than DMSO or DHBA.  
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Figure 3.19. Comparison of different fitting results comparing DMSO and urea dissociation. 
(a), normalized autocorrelation function of control, Aβ containing 80.9% oligomers (rh = 23.3 
nm); (b), after 6 h incubation of 3% v/v DMSO; and (c), after 1h incubation of 8M urea. For 
(c), χ2 (black curve) =0.558, χ
2 (blue curve) =0.313.  
 
 
 
 
 
 
 
65 
 
3.4.2 Significant size change oligomer treatment with urea and GdnHCl 
 
 
Figure 3.20. Hydrodynamic radius measurements of Fl-Aβ oligomers incubated with 
different denaturants as a function of time. a, 8 M urea (closed squares) and 8 M guanidine 
HCl (closed circle); b, adding 0.1% v/v Tween 20 after 19 h incubation with urea 
(urea-Tween-treatment); c, 8M urea + 0.1% v/v Tween 20. 
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The calculated hydrodynamic radius (rh) is plotted as a function of time in Figure 3.20a. Urea 
treatment data is shown as closed squares, and GdnHCl is shown as closed circles. The urea 
treatment alone results in the rapid decrease of size of oligomers from 24.0nm to 15.3nm 
within 2h and then very slow decrease to 14.2nm between 2h to 19h. Dissociation by urea is 
incomplete. Addition of Tween 20 after 19 h incubation with urea induced significant 
decreases in size of the remaining oligomers from 14.2 nm to 2.0 nm within 45 min. The 
initial drop in the size was rapid and leveled out at rh ~2 nm consistent with dimers. The 
appearance of intermediate, ~9.3 nm oligomers was observed within the first 10 min (Figure 
3.20b), and the existence of similar intermediate of oligomer sizes (6 nm and 8.7 nm) was 
also observed for treatment of 8M GdnHCl. 0.1% Tween 20+ 8M urea, added together at time 
zero, induced much faster dissociation than urea alone and almost all the oligomers in the 
mixture broke up into ~2 nm within first 1h as seen in Figure 3.20c which are approximately 
the size of a dimer. 
 
3.4.3 Understanding 2-3 nm species formation 
 
For the lesser dissociation induced by 8M urea the fraction of monomer increased from 15% 
to 57% within 2 h while its size decreased from 24.0 nm to 15.3 nm. For the stronger 
dissociation by GdnHCl, Tween+urea, and Tween added after urea treatment 
(urea-Tween-treatment), the final products of dissociation were particles of 2-3 nm. FCS 
autocorrelation curves in these samples were well described by a simple one-component fit 
suggesting these 2-3 nm particles are the only remaining species in solution with no observed 
oligomers.  
 
Focusing on the samples generated by urea-Tween-treatment, the 2-3 nm species may indicate 
that the multimeric oligomers (rh = 24.0nm) were reduced into smaller oligomers (rh = 14.2nm) 
after 19 h incubation with urea, and then adding the Tween changed the packing to give 
expanded monomers or dimer- or trimer species. However the reformation of dimers or 
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trimers containing at least one FL-Aβ from monomers where there are three non-fluorescent 
Aβ per one FL-Aβ would be relatively unlikely and the total concentration of fluorescent 
dimers should be relatively few.  
 
The distinction between two different molecular species in FCS depends strongly on their 
differences in size as well as their relative concentrations, and the diffusion times of two 
components should differ by at least a factor of 1.6, or ~4x difference in hydrodynamic 
volume for spherical particles [113]. One hypothesis is that the appearance of a few 
dimers/trimers can interfere with the fitting result. This could explain why the FCS results 
showed that dimers/trimers were the only species left in the solution, but in fact there were 
much larger amount of monomers than dimers/trimers. Another hypothesis is there is a 
concentration-dependent effect for the transition between monomers and dimers/trimers. To 
test this hypothesis, we performed a dilution experiment to examine the effects of high 
oligomer concentration on FCS results. Four serial two-fold dilutions were carried out with 
products (~2.8 nm) after 22h of Tween+urea treatment. The measured size of the remaining 
particles decreased from 2.8 nm to 1.7 nm, indicating the high concentration of monomers 
dissociated from oligomers may induce a transition between monomers and dimers/trimers. 
 
Also for the dissociation of oligomers by Tween 20 alone, we observed by FCS that the 
monomer fraction rose considerably. After 24h incubation, there were ~95% monomers 
compared to ~15% before adding Tween20. The remaining ~5% oligomers however were 
observed to have the same size as oligomers before the addition of Tween 20. Therefore, the 
disassembly process caused by urea and GdnHCl must differ from the previously observed 
higher-order cooperative dissociation induced by oligomer exposure to Tween 20, DHBA, and 
DMSO dissociation experiments. Urea and GdnHCl appear to proceed through a linear 
dissociation process where the fraction of monomers increases with time while the size of the 
oligomers simultaneously decreases.  
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3.5 Summary of Aβ oligomers disassembly mechanism 
 
Current descriptions of Aβ oligomer assembly and disassembly mechanism are controversial. 
Most studies are focused on the assembly pathway in amyloid systems. In our study, two Aβ 
oligomer disassembly model are proposed, as described in Figure 3.21. Table 3.2 summarizes 
small molecule dissociators inducing different dissociation mechanisms and their working 
concentrations.  
 
 
Table 3.2. Summary of dissociators studied in this thesis with 
different dissociation mechanisms and their working concentrations 
 
Higher-order cooperative dissociation Linear dissociation 
2,5-, 2,3- and 3,4-DHBA 10μM Urea 8M 
DMSO 3% v/v or 0.45M GdnHCl 8M 
Tween 20 0.1%v/v or 0.9mM 
  
  
 
A linear dissociation mechanism involving destabilizing of oligomer due to binding of small 
molecules, resulted in dissociation of monomer from oligomers with decreasing oligomer size 
(Figure 3.21a) has been hypothesized by several studies. The dissociation kinetics could be 
either mono- [81] or double-exponential [103] depending on the molecular structure of the 
dissociating molecules as well as their potency. In this study, we have directly observed this 
mechanism of dissociation caused by the protein denaturants urea and GdnHCl, by FCS at a 
single-particle level. 
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Figure 3.21. Schematic diagram of two proposed models for amyloid-β disassembly. a, linear 
dissociation; b, higher-order dissociation. 
However, besides linear dissociation, another novel dissociation mechanism has been 
observed with Aβ oligomers exposed to certain DHBA isomers, DMSO, and Tween 20. For 
these molecules, we observe that the fraction of monomer increases at the expense of the 
fraction of oligomers. However, there is no accompanying change in apparent size of the 
remaining oligomers. This suggests a higher-order cooperative dissociation process where a 
nearly instantaneous dissociation of oligomers into monomers is stimulated by the active 
compound (Figure 3.21b). Compared with linear dissociation model, higher-order 
disassembly process seems more effective and potent for targeting oligomers since the 
oligomers are directly converted into nontoxic monomers without producing toxic 
intermediates with a significant half-life.  
In summary, the application of a single-molecule methodology, FCS, provides unique insights 
and a facile way to monitor the Aβ assembly/disassembly pathway at physiological 
concentration. We studied the assembly kinetics of Aβ oligomers in the presence of different 
three active DHBA dissociators and evaluated their different potencies. The results show that 
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DHBA isomers, especially 2,5-DHBA, are prototypes for potential pharmaceutical agents for 
Aβ anti-oligomer therapy. They are relatively water-soluble small molecules of simple with 
strong efficacy to dissociate toxic synthetic Aβ oligomers directly into nontoxic monomers at 
a low dose. Two distinct dissociation models for soluble oligomeric amyloid-β were 
developed, of which the higher-order dissociation model provides a novel insight into drug 
design for treatment of preformed soluble Aβ assemblies in human brain. 
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Chapter Four: Conclusions and Future Work 
4.1 Conclusions 
In the current version of the amyloid cascade hypothesis soluble oligomeric Aβ peptide, rather 
than monomers or fibrils, is considered a primary etiologic agent for AD [122]. As the early 
event in AD pathologic process, the aggregation of Aβ triggers the downstream tau pathology, 
which is better correlated with dementia. Moreover, the formation of small similar oligomeric 
assemblies in other neurodegenerative disease such as Parkinson‟s disease, indicates that they 
could share a common mechanism of toxicity. Therefore it is important to investigate the 
assembly and disassembly kinetics of oligomers which are closely related to the 
amyloid-associated diagnosis and therapy of chronic neurodegenerative diseases.  
Recently a sandwich biotin-avidin interaction based assay was developed to identify the 
assembly dissociation potency and efficacy of a series of dihydroxybenzoic acid (DHBA) 
isomers. However, whether there was formation of potentially toxic intermediates during the 
dissociation was unclear because this type of assay suffers from limited size information and 
oligomers with molecular weight below 40-50kDa are poorly detected.  
The primary aim of this thesis was to harness a single-molecule detection method to provide 
an accurate quantification study of the assembly and disassembly mechanism of Aβ oligomers. 
Our hypothesis was that DHBA isomers enhance the dissociation of oligomers without 
forming potentially toxic intermediates, which was found to be supported by the results. The 
main achievements of this thesis are summarized as the following:  
i) We successfully developed an effective single molecule method to study Aβ oligomer
disassembly mechanisms.
The time course of Aβ1-42 oligomer dissociation at near physiological concentration was 
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investigated in the presence of DHBA isomers (2,5-, 2,3- and 3,4-DHBA) and other 
compounds. Using FCS, we investigated the size distribution of synthetic Aβ oligomers 
trace-labeled with fluorescein-tagged Aβ(1-42) and monitored in real time the change of size 
and mole fraction of oligomers in the presence of dissociating agents or conditions. With 
further confirmation by AFM, it provides the feasibility to evaluate the dissociation potency 
and efficacy of small molecules and to elucidate the specific dissociation mechanism. 
ii) We elucidated a cooperative dissociation mechanism indicating that preformed Aβ
oligomers are a possible therapeutic target and that small molecules can be found that
dissociate oligomers without generating potentially toxic intermediate size oligomers.
This higher-order dissociation process with no transient oligomeric Aβ intermediates 
observed by FCS was first described in the thesis, indicating an avenue to effective 
anti-oligomer therapeutics. DHBA isomers are the first potent small molecules shown to 
stimulate such process. With a differential hydroxyl position-dependent ability, DHBA 
isomers dissociated preformed oligomers following a double-exponential decay kinetics, in 
agreement with the result from the ELISA assay [103].  
iii) We identified at least two distinct Aβ disassembly pathways.
A linear dissociation mechanism with a progressive decrease of size and mole fraction of 
oligomers was observed when soluble oligomeric Aβ was exposed to the protein denaturants, 
urea and guanidine hydrochloride. The possibility of different disassembly pathways, one of 
which produces potentially toxic oligomeric intermediates, suggests that oligomer 
dissociation is responsive to ligand structure.  
The advantages of FCS include high sensitivity, rapid analysis times, and minimal sample 
needed. However, there are still some limitations of the method such as the need to 
fluorescently label samples for measurement and low sample throughput. Assumptions of two 
components (oligomer and monomer) with constant spherical shape must be made. While the 
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Aβ concentration needed to provide a sufficient number of oligomer „events‟ for FCS 
experiments over a range of ratios of Fl-Aβ:WT Aβ in the sample is more physiologically 
relevant than most previous experiments, it is still higher than known concentrations in vivo. 
Also, small changes in oligomer sizes would not be detectable by FCS. Hence, there is a 
continued need for improvement of this method in the future.  
4.2 Future work 
Understanding of the kinetics and disassembly mechanism of toxic oligomeric Aβ peptide 
will contribute to the development of therapeutic agents for treatment of amyloid aggregation 
in AD and possibly shed light on diagnostic approaches and therapeutic treatment of other 
neurodegenerative diseases. In order to thoroughly study the Aβ assembly-disassembly 
process, the employment of effective qualitative and quantitative methods is needed to 
provide a reliable detection of structure or size change of Aβ assemblies, and different 
molecular mechanisms induced by different chemotypes and at what stages those chemotypes 
act need to be clarified. 
4.2.1 Follow time course of dissociation mechanism by atomic force microscopy, AFM 
To complete this project, complementary AFM studies are needed to follow the time course of 
oligomer and monomer sizes and concentration. Due to the limitations of FCS discussed 
above, AFM could be utilized to correlate the mechanisms of protein aggregate dissociation 
suggested by FCS. AFM is capable of directly detecting and characterizing the morphology of 
Aβ aggregates in different sizes at near physiological concentration compatible with 
concentrations needed for FCS. Time course AFM studies would confirm the 
model-dependent results of oligomer dissociation observed by FCS. The smallest Aβ 
oligomers observed by conventional AFM was dimer (~4 nm) [123], thus AFM can solve the 
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resolution difficulties of FCS to distinguish between monomer and dimer/trimer Aβ. 
 
Preliminary work with AFM was performed. By scanning the sample deposited on mica for 
AFM at different times of dissociation, the morphology was obtained and the changes of 
heights were compared with the FCS result. From the AFM topography images of Aβ 
oligomers treated with DMSO within first 1, 2, and 3 hours, the decrease of density of 
oligomers without change of height of oligomers was clear, which was consistent with the 
FCS result described in Chapter 3. These results show the promise of this complementary 
method, for monitoring time course studies of other small molecule dissociators, like DHBA 
isomers and Tween 20, as well as denaturants. 
 
Some issues, however, about sample preparation need to be considered to improve the AFM 
images. For instance, in the denaturant dissociation experiments urea and GdnHCl readily 
recrystallized on the mica surface due to their high concentration (8M). Thus the mica 
samples need to be rinsed thoroughly to remove crystal artifacts on the mica which can be 
considered as “dirt” during scanning by AFM. More concerning, although also interesting is 
the possibility of surface coating of Aβ oligomers and the mica substrate by PEG15-20kDa , 
The PEG15-20kDa coating changes the dimensions of particles and may also interfere with 
binding of Aβ oligomers to the mica. One possible way to reduce the PEG concentration is 
washing through the spin column with oligomer forming buffer after the initial concentration 
with PEG present at the step of centrifugal concentration have coated the membrane filter.  
  
4.2.2 Optimized FCS modeling and fitting method for linear dissociation model 
 
Besides higher-order cooperative dissociation by DHBA isomers and Tween 20, a linear 
dissociation model was observed in the presence of protein denaturants, urea and GdnHCl 
suggesting a progressive release of monomers from oligomers with production of smaller 
oligomer intermediates. However, the simple two-component fit method for FCS data 
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analysis is inadequate for properly analyzing multi-component systems, such as multiple 
oligomeric intermediates of various sizes. An optimized modeling and fitting method needs to 
be developed. 
A possible example or starting point for this is MEMFCS (maximum entropy method-base 
analysis of FCS data). This method analyzes FCS data in the model of a continuous 
distribution of diffusion species, and also seeks a maximum entropy distribution that is in 
agreement with all the experimental data [124]. The idea of maximum entropy has been 
widely used for image reconstruction from noisy and incomplete data, for which a general 
algorithm was first proposed by Skilling and Bryan [125]. For amyloid aggregation FCS 
studies, it has been applied to evaluate the stability of soluble Aβ oligomers at different pHs 
and ionic strength [126] and in the presence of divalent metal ions [88]. Hence, MEMFCS 
allows reliable descriptions of heterogeneous systems and can give an accurate quantification 
of numbers of oligomers of different sizes in a heterogeneous population, even though for 
highly complex specimens the method is time-consuming due to the massive computational 
requirement.  
4.2.3 Study of a new oligomer assembly modulator: assembly inhibitors 
The finding of linear dissociation model would not be “good news” for an oligomer targeting 
therapeutic due to the risk of forming toxic oligomeric intermediates. Previous study showed 
DHBA isomers have a hydroxyl position-dependent ability to dissociate preformed oligomers, 
but no have effect on assembly [103]. This is unlike clioquinol and other 8-hydroxyquinoline 
derivatives, which block oligomer formation at the stage of monomer or low n-mer formation 
[102]. Therefore, there are two different modes of oligomer assembly modulation, 
dissociation enhancers and assembly inhibitors which can be distinct. The former, which 
seems more promising, could target the oligomer which is already formed in the brain of AD 
patients to prevent AD or to slow down the progression of the disease.  
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